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ABSTRACT 
The cannabinoid receptors (CB1 and CB2) belong to the family of class A GPCRs. The 
CB1 receptor is predominately found in the central nervous system and regulates various 
neuromodulatory and physiological processes while CB2 receptors are found in peripheral 
tissues, particularly in the immune system tissues. This dissertation reports several projects 
including: (1) an examination of the putative binding modes of Cannabis-derived ligands with 
CB1 and CB2 receptors, (2) the identification of novel CB1 inverse agonists, and (3) the 
identification of allosteric site(s) in the CB2 receptor and screening of new CB2 allosteric 
modulators (AMs).   
Chapter 1 describes background information on cannabinoids and the endocannabinoid 
system. Chapter 2 focuses on the structure-activity relationships of Cannabis-derived ligands 
with CB1 and CB2 receptors. These compounds are known to exhibit nanomolar to micromolar 
affinities against the CB1 and CB2 receptors; however, little-to-no information is available about 
how they interact with the receptors at the molecular level. To understand the putative binding 
interactions of these ligands with the CB receptors, molecular docking and binding free-energy 
calculations were performed. The modeling results agree well with the experimental results and 
delineate key residues of CB1 and CB2 receptors that are engaged in H-bonding, aromatic 
stacking, and hydrophobic interactions with the ligand. Chapter 3 focuses on the identification of 
new CB1 inverse agonists using protein structure-based virtual screening. These compounds 
exhibited nanomolar to micromolar binding affinities against the CB1 receptor and antagonized 
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basal GTPγS functional activity consistent with inverse agonist behavior. These compounds 
represent novel scaffolds that could be used to develop new CB1 inverse agonists with fewer or 
null psychiatric side effects compared to rimonabant. Chapter 4 focuses on the identification and 
characterization of CB2 allosteric site(s). Using known CB2 negative AMs, the binding energy 
of representative complexes after molecular dynamics studies validated the binding poses of 
AMs. Virtual screening revealed seven potential AMs and they have been submitted for in vitro 
testing. The results from this study could lead to the discovery of more effective and selective 
CB2 AMs. Finally, Chapter 5 includes the summary and conclusions of the research presented in 
this dissertation. 
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1.1. Introduction 
The G-Protein Coupled Receptors (GPCRs) are integral membrane proteins which 
represent the largest single group of targets for approximately 40-50% of FDA approved drugs, 
and functional selectivity of these targets may permit novel approaches to drug design (1-3). 
GPCRs are widely distributed only in eukaryotes, including yeast, choanoflagellates, plants and 
animals (4, 5); however, recently they were also found in fungi (6). There are at least 800 GPCRs 
identified in the human genome (7, 8). Many GPCRs do not have known ligands and are referred 
to as orphan GPCRs.  
1.1.1. General structural features of GPCRs 
The basic structure of GPCRs are characterized by an extracellular amino (N)-terminal 
segment, followed by seven transmembrane (7-TM) alpha-helix segments (TM-1 to TM-7), 
connected through three extracellular loops (EC1, EC2 and EC3) and three intracellular loops 
(IC1, IC2 and IC3) and an intracellular carboxyl (C)-terminal segment (Figure 1.1). These 
extracellular loops also contain two highly conserved cysteine residues that form disulfide bonds 
to stabilize the receptor structure. The extracellular N-terminal part of the receptor participates in 
glycosylation and ligand binding, while the intracellular C-terminal part of GPCRs participates 
in G-protein binding, desensitization, and internalization (9-11).  
The 7-TM region is known to contain well-conserved motifs that are characteristics of 
GPCRs; however, the structural diversity among the members of the same subfamily still makes 
prediction of 3D protein structure using homology or comparative modeling challenging. 
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Figure 1.1. The basic structure of GPCRs. 
1.1.2. Classification of GPCRs 
Kolakowski proposed the first classification of GPCRs system in 1994; he grouped 
GPCRs into 6 classes based on sequence homology and functional similarity (12). These classes 
were as follows: Class A (rhodopsin-like), Class B (secretin receptor family), Class C 
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(metabotropic glutamate), Class D (fungal mating pheromone receptors), Class E (cyclic AMP 
receptors) and Class F (frizzled/smoothened).  
Later in 2005, Fredriksson et al. introduced an alternative classification system known as 
GRAFS (13). According to the GRAFS (Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, 
Secretin) classification system, vertebrate GPCRs were grouped into 5 classes (13).  
Metabotropic glutamate/pheromone (former class C): The metabotropic receptor or 
glutamate receptor-like family has been classified previously as class C family. The 
metabotropic receptor is comprised of 8 subclasses (subfamilies) and members all form dimers 
and include the metabotropic glutamate receptors (mGluR), extracellular Ca2+-sensing receptors, 
taste (gustatory) receptors, and several odorant receptors, as well as the pheromone receptors. 
Rhodopsin family (former class A): The rhodopsin family was referred to previously as class A 
GPCR family. The rhodopsin family contains the largest number of members compiled into at 
least 19 subclasses (subfamilies). This class, which includes rhodopsins, adrenergic receptors, 
opioid, and cannabinoid receptors, shares highly conserved regions. These include the Glu/Asp-
Arg-Tyr (E/DRY) motif on the intracellular side of TM3, the CWXP in TM6 and an Asn-Pro-X-
X-Tyr (NPXXY) motif in TM7. 
Adhesion family: This class is phylogenetically related to the previously classified class B 
receptors. It includes polycystic kidney disease 1 (PKD1)-like proteins. 
Frizzled/Smoothened (former class F): The Frizzled/Smoothened has been classified 
previously as Family F. These play important roles in embryonic development and especially in 
cell polarity and segmentation. 
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Secretin receptor family (former class B): The secretin-like receptor class was classified 
previously as the class B GPCR family. The secretin receptor family is comprised of 34 
subclasses (subfamilies) and members include receptors for peptide hormones, such as 
parathyroid hormone (PTH), parathyroid hormone-related protein (PTHrP), and calcitonin. The 
class B family also contains the vast majority of the orphan GPCRs. 
Classes D and E are not included in this system because they are not part of the human genome 
(13). 
Class D (Fungal mating pheromone receptors): Family D comprises pheromone receptors 
(VNs) associated with the inhibitory G protein (Gi). 
Class E (Cyclic AMP receptors): Family E refers to cAMP receptors (cAR), which have only 
been found in D. discoideum, however no information is available about its possible expression 
in vertebrates (14-16). 
1.1.3. GPCR ligands and receptor state terminology 
Ligands are those molecules that bind to GPCRs and regulate their activation and, 
subsequently, alter their biological functions. Ligands can either act on the orthosteric site (also 
known as the agonist binding site) or an allosteric site (also known as a regulatory site). The 
agonist-binding site (orthosteric site) is well conserved in most GPCRs. In contrast, allosteric 
sites are structurally distinct from and less well-conserved compared to the active site of the 
agonist site in the same protein; therefore, allosteric sites can offer a better target to avoid side 
effects associated with orthosteric binding site agonists. Some GPCRs possess intrinsic activity 
in the absence of either endogenous or synthetic ligands. This intrinsic activity of a receptor is 
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referred to as constitutive activity or basal activity. In general, the constitutive activity of GPCRs 
results from an equilibrium state where some receptors are present in the ground state with no 
activity (R) and others are in their fully activated state (R*). Agonists are those molecules that 
bind to the active state of the receptor and promote its biological function via signal transduction, 
while inverse agonists bind to the inactive states of the receptor and block constitutive activity of 
the GPCR and agonists’ effects. Antagonists are those compounds that act on the GPCR binding 
site and block the binding and activation of agonists without altering the distribution of inactive 
and active states. Moreover, neutral antagonists are those molecules that block the binding of 
agonists as well as of inverse agonists but exert no efficacy for their cognate receptor (17).  
1.1.4. GPCR signaling 
G-proteins are heterotrimeric and comprised of α, β, and γ subunits. The α subunit not 
only plays an important role for GDP and GTP binding, but it is also responsible for GTP 
hydrolysis, whereas the β and γ subunits are in a strongly linked βγ dimer. G-proteins are 
generally referred to by their α subunits. Currently, four distinct α-subunit subfamilies have been 
reported: Gs proteins (s = “stimulatory”) couple to and stimulate adenylyl cyclase; Gi proteins (i 
= “inhibitory”) couple to and inhibit adenylyl cyclase as well as activate G-protein-coupled 
inwardly rectifying potassium (GIRK) channels; Gq proteins couple to the activation of 
phospholipase C (PLC) which generates second messengers (e.g., vasopressin, thyroid-
stimulating hormone, angiotensin); and Gt proteins (t = “transducing”) couple to trigger the 
breakdown of cyclic GMP (cGMP) .  
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Figure 1.2. Classical examples of Class-A GPCR signaling. This image has been reproduced 
with permission of the American Chemical Society under copyright license number 
3733750761285. 
In the absence of ligand, whether endogenous, synthetic, or plant-derived, integral 
transmembrane GPCR receptors such as the rhodopsin or β2 adrenergic receptor (β2-AR) present 
in the low-affinity state. When an agonist binds to the receptor, it activates the receptor in such a 
way that it forms a transient high-affinity complex of agonist, activated receptor and G protein. 
During this process, GDP is released from the G-protein due to conformational changes in the G 
protein and is replaced by GTP. This sudden change causes the dissociation of the G-protein 
complex into α subunits and βγ dimers and subsequently both act on various intracellular effector 
pathways. Gs protein, for example, activates adenylyl cyclase, which leads to an increase in 
cyclic AMP (cAMP). This increased cAMP ultimately activates protein kinase A (PKA), which 
generally phosphorylates substrates of interest, including GPCRs, other kinases, and 
transcription factors (Figure 1.2) (18-20). 
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Receptor trafficking or desensitization generally starts when an agonist activates a GPCR. 
The activation of the receptor leads to the dissociation of G-protein subunits into an α subunit 
and a βγ dimer. The free βγ dimers recruit G-protein-receptor kinases such as GRK2/3 to the 
receptor, where they specifically phosphorylate serine/threonine residues of agonist-bound 
receptors in their third intracellular loop and C-terminal domain. This phosphorylation process 
allows the recruitment of β-arrestin to the receptor and internalization of the receptor–β-arrestin 
complexes take place into clathrin-coated pits. Again, this receptor-β-arrestin complex gets 
internalized into acidic endosomes and then either degraded by lysosomes or dephosphorylated 
and returned to the surface of cell (Figure 1.3) (10, 11, 18).  
Figure 1.3. Seven-transmembrane (7-TM)-receptor trafficking.	  This image has been reproduced 
with permission of the American Chemical Society under copyright license number 
3733750761285. 
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1.1.5. Endocannabinoid system 
The extensive research in the field of cannabis contributed to the understanding of the 
mechanism of action of cannabis and its receptor interactions through the discovery of the 
endocannabinoid system. The endocannabinoid system is made up of the cannabinoid receptors 
(CBrs), their associated endogenous ligands, such as N-arachidonoylethanolamine (anandamide) 
and 2-arachidonoylglycerol (2-AG) and the enzymes which are involved in the synthesis, such as 
phosphatidic acid phosphohydrolase, diacylglycerol lipase (DAGL), phosphoinositide-specific 
PLC (PI-PLC) and lyso-PLC, transportation and degradation of the ligands, such as fatty acid 
amidohydrolase (FAAH) and monoacylglycerol lipase (MAGL) (21). So far, there are two 
identified CB receptor subtypes: CB1 (22) and CB2 (23), and at least five endogenous (24-28) 
cannabinoids (anandamide, noladin ether, virodhamine, 2-AG and N-arachidonyldopamine) 
produced by the human brain. Recently, GPR55 has been identified as a third type of 
cannabinoid receptor (29). The cannabinoids can be classified into three categories: 
“phytocannabinoids”, mainly present in the cannabis plant (“Cannabis sativa”), “endogenous 
cannabinoids”, produced by humans and other animals; and “synthetic cannabinoids” belonging 
to similar compounds synthesized in a laboratory. The endocannabinoid system is widely 
distributed throughout the brain, immune system, and especially the spinal cord; it plays a role in 
many regulatory physiological processes including inflammation, appetite regulation, 
metabolism, energy balance, thermogenesis, neural development, immune function, substance 
abuse and digestion (30-32). 
1.1.6. Timeline for cannabinoids, receptor system and endocannabinoid research  
The plant Cannabis sativa and its many preparations (i.e., hemp, hashish, bhang, hash oil, 
and ganja) have been used for recreational as well as medicinal purpose for centuries (33). 
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Cannabis, also known as marijuana, is one of the most illicit drugs in the world and widely used 
in a cigarette commonly known as joint or nail. The U.S. Drug Enforcement Administration lists 
cannabis/marijuana as Schedule I substance, under the Controlled Substances Act (34). At 
present, four U.S. states (Alaska, Colorado, Oregon, and Washington) have legalized the sale or 
use of cannabis for both recreational and medicinal purposes, and a total of 23 US states and 
Washington, DC have legalized cannabis for medicinal use (35). The identification of ∆9-THC, a 
key active constituent of the cannabis plant which is present in the significant quantity and which 
has shown psychoactive efficacy, provided the platform for extensive research for 
pharmacological action, structure exploration studies such as structure activity relationships and 
lead optimization, discovery of cannabinoid and non-cannabinoid receptor, and synthesis of 
highly selective and potent analogs (36). 
Initially, the term cannabinoid was used to refer to cannabis-like agents or cannabinol and 
describe only 21-carbon structures which belonged to the chemical class of terpenophenolic 
compounds and related analogs present within cannabis and its preparations (37). More recently, 
the term cannabinoid includes a vast variety of ligands which have activity at the cannabinoid 
receptors, including synthetic and/or endogenous compounds.  
The following discoveries from the year 1838 to 2015 provided the fundamental basis to 
understand the mechanism of action involved in the pharmacological actions of cannabis (29, 38-
41). 
• 1838-1843 An Irish physician, O’Shaughnessy, investigated the therapeutic use of 
cannabis in India 
• 1899 Isolation of first plant cannabinoid, cannabinol 
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• 1932-1940 Cannabinol structure elucidation 
• 1940 Cannabidiol isolation 
• 1941 Synthesis and evaluation of ∆6a,10a-THC  
• 1942-1950 Early pharmacological investigations 
• 1963 Cannabidiol structure elucidation 
• 1964 Gaoni and Mechoulam, first structure elucidation of ∆9-THC from cannabis  
• 1964-1975 Isolation and identification of additional cannabinoids 
• 1972 Ring immobility and tetrad assays developed by Martin 
• 1974 Pfizer Central Research synthesized and patented CP 55,940 
• 1988 Discovery of CB1 receptor 
• 1990 Matsuda et al. provided the first definitive poof of a central cannabinoid 
receptor (CB1) by cloning of CB1 receptor 
• 1991 Stirling-Winthrop Research Group discovered the indole cannabinoids 
Win 55212-2 
• 1992 Devane et al. isolated and characterized the first endogenous ligand 
(anandamide) to the cannabis receptor  
• 1993 Munro et al. discovered a second cannabinoid receptor, CB2 which was isolated 
from human myeloid cells  
• 1994 Sanofi introduced the first selective CB1 antagonist SR141716A  
• 1995 Isolation and structure elucidation of second endogenous ligand, 2-AG 
• 1995 GPR55 was identified and cloned 
• 1996 Cloning of the first endocannabinoid-degrading enzyme, FAAH 
• 1998 Sanofi introduced the first selective CB2 antagonist SR144528  
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• 1999- 2000 Anandamide activates vanilloid receptors 
• 2001-2014  Discovery of retrograde signaling by endocannabinoids; Discovery and 
evaluation of endocannabinoid-like brain components, discovery and evaluation of 
functions of FAAH and MAGL inhibitors, cell biology and neuroscience studies 
carried out and clinical trials initiated 
• By 2015: At least 111 cannabinoids identified from Cannabis sativa  
1.1.7. Classification of cannabinoids 
1.1.7.1. Phytocannabinoids (naturally-occurring plant cannabinoids) 
  Phytocannabinoids are those cannabinoids that occur naturally in the Cannabis sativa 
plant. The plant genus Cannabis belongs to the plant family Cannabaceae. Cannabis has three 
primary species, which vary in their biochemical constituents: Cannabis sativa, Cannabis indica, 
and Cannabis ruderalis. Cannabis can be classified as marijuana or hemp depending on the ratio 
of Δ9-THC and cannabidiol (CBD).  
 
 
 
 
 
 
Figure 1.4. Important cannabinoids found in Cannabis sativa. 
In general, cannabis that contains higher amounts of Δ9-THC, and lower amount of the 
non-psychoactive cannabinoid, cannabidiol (CBD), is referred to as “marijuana.” Cannabis that 
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contains high levels of CBD, and very low levels of Δ9-THC, is referred to as “hemp,” or 
“industrial hemp,” and has no psychoactive effects (42, 43). 
The well-known phytocannabinoids are THC (tetrahydrocannabinol) and CBD 
(cannabidiol), but the cannabis plant also contains CBG (cannabigerol), CBC 
(cannabichromene), and THCV (tetrahydrocannabivarin) (Figure 1.4). These are the most 
important cannabinoids found in Cannabis sativa, the plant containing a total of 111 
cannabinoids to date (41, 44).  
Δ9-THC was first isolated in 1964 (45), and is a partial agonist at 
both CB1 and CB2 receptors, but also acts at other non-CB 
receptors (such as opioid and benzodiazepine receptors). It is a 
highly lipophilic, volatile viscous oil with poor aqueous 
solubility and a pKa of 10.6 (46). Its actions at the CB1 receptor 
accounts for the psychoactive effects of cannabis and might be 
due to suppression of both glutamate and GABA release (47). Its 
pharmacological action and efficacy were determined by various 
clinical trials where it showed multiple therapeutic benefits such 
as an analgesic, antiemetic, antidepressant, and appetite 
suppressant/stimulant, in a treatment of glaucoma, and for the 
management of chemotherapy-induced nausea and vomiting (48-
50). 
Figure 1.5. A major metabolic pathway of Δ9-THC. 
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THC exists in two isomeric forms known as ∆9-THC and ∆8-THC. They differ only in the 
position of the double bond at C-9 and C-8 (Figure 1.6). Δ8- and Δ9-THC have shown equivalent 
receptor affinity and pharmacological activity to cannabinoid (CB) receptors but Δ8-THC has the 
advantage of being the thermodynamically more stable isomer (51). In human, the metabolism of 
Δ9-THC by enzymatic hydroxylation (a major metabolic pathway) leads to the formation of an 
active metabolite (11-hydroxy-Δ9-THC), which is further oxidized to an inactive acid (THC-
COOH). These metabolites get conjugated in fatty tissues which increase the stability of these 
metabolites. Further, these fatty acid-conjugated metabolites are released slowly for several 
weeks and can be detected in urine after cannabis use (Figure 1.5) (46). 
 
 
 
Figure 1.6. THC exists in two isomeric forms. 
1.1.7.2. Endogenous cannabinoids 
Endocannabinoids are the substances that are naturally produced or made on demand by 
the human body to stimulate cannabinoid receptors. The biosynthetic pathways of 
endocannabinoids anandamide (AEA) and 2-AG (Figure 1.7) have been well investigated and 
understood (52-54). These endocannabinoids exert local effects before being degraded by the 
endogenous enzymes such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase 
(MAGL). AEA, a fatty acid amide, was first isolated and characterized by Devane et al. (1992) 
(24). AEA is synthesized postsynaptically on demand in vivo at very low levels and degrades 
rapidly by FAAH, which breaks it into arachadonic acid and ethanolamine. This explains why it 
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exhibits a short half-life (24). It also activates the transient receptor potential vanilloid 1 
(TRPV1) with low binding affinity. Functionally, it is a full agonist at the TRPV1 receptor (55). 
2-AG is an endogenous arachidonic acid derivative which was first isolated and 
characterized by Mechoulam et al. in 1995 from dog intestine (27). 2-AG acts in a retrograde 
fashion to inhibit GABA or glutamate release from presynaptic terminals and shows promising 
pharmacological responses including neuroprotection and cardioprotection (56, 57). The 
occurrence of 2-AG in brain is relatively high as compared to AEA and it is synthesized by the 
hydrolysis of diacylglycerol (DAG) by DAG-lipase (DGL). 2-AG is hydrolyzed by the 
membrane bound enzyme monoacyl glycerol lipase (MAGL). 
More recently, noladin ether (CB1/CB2 agonist), virodhamine (CB1 partial 
agonist/antagonist and CB2 agonist) and N-arachidonyl-dopamine (CB1 agonist) were identified 
as endogenous endocannabinoids; however the mechanisms of action of these endocannabinoids 
are still unclear. The structures of all five endocannabinoids are shows in Fig 1.7. 
4
CH2 3 R
n-C4H9
 
Where R = CONH(CH2)2OH (Anandamide), R = CO2CH(CH2OH)2 ( 2-Arachidonylglycerol) 
, R= CH2OCH(CH2OH)2 (Noladin ether), R = CO2(CH2)2NH2 (Virodhamine) 
R = CONH(CH2)2-3,4-(OH)2-Phe (N-Arachidonyl-dopamine (NADA)) 
Figure 1.7. Structures of known endocannabinoids. 
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1.1.7.3. Synthetic cannabinoids  
There are several recognized cannabinoid receptor agonists and antagonists that showed 
better affinity and selectivity over CB1 and CB2 receptors (Figure 1.8). Non-selective CB1/CB2 
agonists often contain chiral centers and exhibited a significant impact of stereoselectivity in the 
pharmacological assays. As to the aminoalkylindole, WIN 55,212, R-(+)-WIN 55,212-2 is more 
active (Ki = 1.89-123 and 0.28-16.2 nM at CB1 and CB2, respectively) than S-(-)-WIN 55,212-3, 
while (–)-trans (6aR, 10aR) classical Δ9-THC (Ki = 5.05-80.3 and 3.13-75.3 nM at CB1 and 
CB2, respectively), HU 210 (Ki = 0.06-0.73 and 0.17-0.52 nM at CB1 and CB2, respectively) 
and non-classical (CP 55,940) cannabinoids exhibit significantly greater potency as cannabinoid 
receptor agonists than their (+)-cis (6aS, 10aS) enantiomers. The most commonly used non-
selective CB agonist is CP 55,940 (Ki = 0.5-5.0 and 0.69-2.8 nM at CB1 and CB2, respectively). 
The CB1-selective cannabinoid receptor inverse agonists/antagonists are rimonabant 
(SR141716A), AM 251 (Ki = 7.49 nM at CB1 and is 306-fold selective over CB2), and AM 281. 
Recently, researchers identified a set of neutral CB1 receptor antagonists, such as O-2050 (a 
sulphonamide analogue of Δ8-THC with an acetylenic side chain) and two SR141716A 
analogues, VCHSR and NESS 0327. The best CB2-selective agonists to have been developed so 
far are HU 308 (Ki values are 22.7 nM and > 10 µM for CB2 and CB1, respectively), AM 1241, 
JWH 133 (Ki values are 3.4 and 677 nM at CB1 and CB2, respectively), and GW 405833. For 
CB2-selective inverse agonist/antagonists, the best known of these are SR144528, AM 630 (CB2 
Ki = 31.2 nM and is 165-fold selective over CB1) and JTE 907 (Ki values are 0.38, 1.55 and 
35.9 nM at rat, mouse and human CB2, respectively). The most widely used tritiated cannabinoid 
receptor ligands in the field of radioligand receptor binding assays or for autoradiography are 
[3H]-SR141716A (CB1-selective inverse agonist, CB1 Kd = 0.19 to 1.24 nM) and the non-CB 
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selective agonists ([3H]-CP 55,940, [3H]-WIN 55,212-2 and [3H]-HU 243) (34, 58). The 
abbreviated codes of well-studied compounds (see Table 1.1) infer the name of the 
inventor/company and not the chemical or pharmacological class of compound. 
Table 1.1: The abbreviated codes of well-studied cannabinoid compounds 
 
1.1.8. Cannabinoid-based drugs on the market  
Rimonabant, a well-known CB1 receptor inverse agonist approved for obesity treatment 
in European countries, was withdrawn from the market due to severe adverse effects such as 
depression and increased incidence of suicidal tendencies (59). Currently three marketed 
cannabinoid formulations are available: 
Dronabinol (Marinol®) is the first synthetic Δ9-THC, approved by the United States Food and 
Drug Administration (USFDA) in 1985. This drug is used to treat cancer chemotherapy-induced 
nausea and vomiting, and as an appetite stimulant for anorexic and AIDS patients (35, 60) 
AM Alexandros Makriyannis 
CP Central Pfizer 
HU Hebrew University, Jerusalem, Israel 
JTE Japan Tobacco Inc. Japan 
JWH John W. Huffman, Clemson University, South Carolina, USA 
SR Sanofi Recherche. Later Sanofi Winthrop; now Sanofi-Synthelabo 
Win Stirling-Winthrop Inc. Later Sanofi-Winthrop; now Sanofi 
Synthelabo 
O Organix Inc. USA 
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Nabilone (Cesamet®) is a synthetic analog of Δ9-THC approved in 2006 by USFDA. This drug 
is used as an antiemetic for patients who are not responsive to standard antiemetics and as 
adjunct therapy for neuropathic pain (35).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Structures of commonly known synthetic cannabinoids. 
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Sativex is a cannabinoid medicine, which is a 1:1 ratio of THC and CBD in the form of an 
oromucosal spray. It was developed by GW Pharmaceuticals, a company from United Kingdom, 
and was approved in Canada in 2005 for multiple sclerosis patients to alleviate spasticity. 
Sativex has been launched in 15 countries over the past few years. New therapeutics benefits of 
this drug, such as for treating cancer pain, are in Phase 3 clinical trials (35, 61). 
1.1.9. Peripherally-restricted CB1 inverse agonists/antagonists 
To avoid the central nervous system-related side effects of CB1 antagonism, a new 
strategy adapted to make peripheral restricted CB1 antagonist that do not cross the blood-brain 
barrier (BBB). Many researchers followed this strategy and reported a number of CB1 
antagonists that do not cross the BBB (Figure 1.9) (62-67). Obesity is a medical condition 
accompanied by leptin resistance, which ultimately alter the anorexic and weight-reducing 
effects of leptin (68). In other words, obesity has a direct correlation with abnormalities in leptin 
signaling. Leptin is a hormone produced by fat cells that regulates long-term energy balance in 
the body (69). Excess of leptin also called hyperleptinemia plays a critical role in leptin 
resistance, and leptin sensitivity is restored when leptin level is lower in plasma through dietary 
weight loss. CB1 receptor knockout (CB1R−/−) mice exhibit increased leptin sensitivity, which 
further validates that reversal of leptin resistance contributes to the antiobesity effect of CB1 
blockade (70). Tam et al. (2012) explained the mechanism by which peripheral CB1R blockade 
O
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H
O
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may affect the leptin sensitivity in the hypothalamus. Tam’s results suggested that peripheral 
CB1R inverse agonist such as JD5037, reverses hypothalamic leptin resistance in diet-induced 
obesity (DIO) mice, by two process; 1) decreased leptin secretion by adipose tissues and, 2) 
increasing leptin clearance via the kidney (71).  
 
Figure 1.9. Reported peripheral CB1 antagonists/inverse agonists. 
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1.1.10. Cannabinoid receptors 
Cannabinoid receptors (CB) belong to the rhodopsin-like GPCRs family and are activated 
by the cannabinoid ligands. In general, cannabinoid ligands are classified into three major 
categories: 1) endocannabinoids, 2) plant cannabinoids, and 3) synthetic cannabinoids. There are 
mainly two known subtypes of CB receptors reported, including cannabinoid receptor 1 (CB1) 
and cannabinoid receptor 2 (CB2). The CB1 and CB2 receptors were characterized and cloned in 
1990 and 1993, respectively (22, 23). The human CB1 and CB2 receptors exhibit ~44% 
sequence identity over the entire amino acid sequence and ~74% sequence homology between 
CB1 and CB2 receptors between their seven transmembrane region (Figure 1.10). 
 
 
 
 
 
 
 
Figure 1.10. Sequence alignments of the human CB1 and CB2 receptors. Identical and highly 
similar residues are colored red and blue, respectively. Residues with low similarity are colored 
green, yellow-shaded residues belong to the 7-TM domains. 
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Abood et al. (1997) has reported CB1 genomic clone, which reveals 99.5% amino acid 
identity between mouse and rat, and 97% amino acid identity between mouse and human CB1 
(72). The CB1 receptor is predominantly expressed in the CNS, although it is also expressed in 
the peripheral system, including lungs, liver, and kidneys (73). CB receptors have been identified 
in many other vertebrates, including birds, amphibians, and fish; however, they are absent in 
insects (74). Currently, two splice variants of human CB1 are found to exist in vivo. These splice 
variants differ mainly in the length of their extracellular amino terminus. The first variant hCB1a 
was cloned in 1995 and it lacks first 61 amino acids of the amino terminus of hCB1(75). The 
second splice variant of the coding region was identified in 2005 as hCB1b, which was shown to 
have a deletion of 33 amino acids from the CB1 N terminal (76). The splice variants (hCB1a and 
hCB1b) did not show any affinity or efficacy with endogenous endocannabinoids such as 
arachidonoyl ethanolamide, noladin ether and virhodamine; however, only 2-AG showed 
minimal binding and activation of hCB1a or hCB1b receptors. Andersson et al. 2003, has 
showed that first 89 amino acids from N terminus of CB1 can be deleted and have no effects on 
binding and efficacy to the ligand CP 55,940 (48). 
In particular, the CB1 receptors are well studied for their key role in the regulation of 
food intake, fat accumulation and lipid and glucose metabolism through the central and 
peripheral system (77). Dysregulation of any of these functions leads to CB1 hyperactivity (78) 
in both central nervous system and peripheral tissues (adipose tissues, skeletal muscle cells, liver, 
kidney, gastrointestinal tract). Stimulation of hypothalamic CB1 receptors with agonists or 
neuropeptides control energetic homeostasis, food intake and lipogenesis in visceral tissues (79). 
Expression of CB1 receptor is higher in the hippocampus region of brain and is related to the 
disruptive effects of cannabinoids on memory and cognition (80). The level of CB1 receptor 
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expression and its binding decreased in neurodegenerative diseases, such as Parkinson’s (81) and 
Huntington’s (82). In addition, stimulation of CB1 receptors in the nucleus accumbens activates 
the dopaminergic reward pathway and increases the appetite and the motivation to smoke or take 
drugs of abuse (83). Furthermore, the presence of CB1 receptors in the dorsal horn of the spinal 
cord and the periaqueductal gray also correlates with the pain modulation (84). 
CB2 receptor is predominantly expressed in the peripheral areas of the body, especially in 
the immune and skeletal systems such as B-lymphocytes, macrophages, microglia, natural killer 
cells, peripheral mononuclear cells, CD4 lymphocytes, CD8 lymphocytes, lymph nodes, Peyer’s 
patches, spleen, tonsils, and thymus (73, 85-87). Griffin et al. (2000) has performed sequence 
analysis of the coding region of the rat CB2 and provide the evidence that 93% amino acid are 
identical between rat and mouse while only 81% amino acid are identical between rat and human 
(88). CB2 receptors are implicated in the treatment of several other human diseases/disorders: 
Osteoporosis: CB2 receptors are expressed in bone cells, and CB2 receptor knockout 
experiments have demonstrated the therapeutic potential of CB2 receptor antagonists for the 
treatment of osteoporosis (89).  
Multiple sclerosis: Cannabinoids are emerging as potential candidates for treatment of multiple 
sclerosis through activation of CB2 receptors expressed in perivascular microglial cells in the 
human brain (90). 
Allergic contact dermatitis: The CB2 receptor appears to be involved in allergic contact 
dermatitis; however, it is not clear whether a CB2 agonist or an inverse agonist/antagonist would 
be therapeutically beneficial (91).  
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Ischemia/reperfusion injury: A protective role for the CB2 receptor has been demonstrated in 
hepatic, cardiac, and cerebral ischemia/reperfusion injury. It has been confirmed through 
experiments using CB2 receptor knockout mice (92, 93).  
Atherosclerosis: While selective CB2 agonists remain to be tested, impressive efficacy in 
reducing progression of atherosclerosis has been demonstrated with a non-selective CB agonist 
(94).  
Colitis: The potential role of the CB2 receptor is implied in colonic inflammation (95). 
Uveoretinitis: There is some evidence that CB2 agonists could be therapeutically beneficial for 
treating autoimmune uveoretinitis, but this needs further experimentation (96).  
Cough: Inhibitory potential on airway sensory nerves and its antitussive activity in guinea pigs 
has been confirmed using a highly selective CB2 agonist (61). 
1.1.11. Selective CB2 agonists undergoing clinical trials 
CB2 agonists have the potential to provide therapeutic benefit for a number of conditions or 
disease states either needing more effective and safe medicines or those that fall into the category 
of “unmet medical need”. Several pharmaceutical companies have started the development of 
selective CB2 agonists (JBT-101, ABT-521, GRC10693, LY2828360, AZD1940, KHK6188, 
CR701, APD371 and S-777469), mostly for the treatment of pain. A significant number of 
clinical trials by different organizations, including JB Therapeutics, Kyowa Hakko Kirin, Eli 
Lilly, Astra Zeneca, Shionogi, Arena, and Abbott, have advanced to Phase I and Phase II clinical 
trials with various CB2 agonists (97). 
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1.1.12. CB1 and CB2 structural features 
CB1 and CB2 receptors also share the functional motifs that are conserved among most 
family A GPCRs. These include the S(N)LAxAD in TM2, E/DRY in TM3, CWXP in TM6, and 
NPXXY in TM7.  
Since no crystal structure is available for either CB1 or CB2 receptor to date, many 
researchers have utilized homology modeling in the creation of 3D structure of CB1 using the 
human β2AR as a template.  
CB1 and CB2 receptors both possess a single disulfide bond within EC2 loop region: 
residues 174 and 179 in CB1 (98) and residues 257 and 264 in CB2 (99). 
The modeling study of CB1 receptor by Salo et al. 2004 utilized the human β-adrenergic 
receptors as templates (100), and suggested the presence of the TM1-TM2-TM7 hydrogen-
bonding network near the S(N)LAxAD motif that are resembles in reported conserved residues 
of rhodopsin. Following H-bonding network has analyzed: 
1. A large H-bond network was formed between Asn134 (H1)/ Asp163 (H2), and Asp163 
(H2)/Asn393 (H7) of the CB1 receptor. Similar H-bond network are conserved in 
rhodopsin connecting Asn55 (H1), Asp83 (H2), and Asn302 (H7).  
2.  H-bond cluster located at extracellular core region of H3/H5 involves the interaction 
between Thr201 (H2)/Thr283 (H5), and between Thr197 (H2) and Tyr275 (H5) or 
His270 (H5).  
In addition, an H-bond network was also found near the CWxP motif surrounded by 
Cys355 (H6), Cys382 (H7), and Cys386 (H7). 
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Modeling studies have also revealed that stability of the inactive CB1/CB2 receptor 
conformation can be governed by two important salt bridges or ionic locks (100) and toggle 
switches (101): 
1. Ionic lock, between Arg214 of the E/DRY motif on TM3 and Glu338 on TM6 of the CB1 
receptor, while Arg131 and Asp240 at the intracellular ends of TMH3/6 region of CB2. 
2. The second ionic lock between Asp176 on TM2 and Lys192 on TM3 of the CB1 receptor 
while CB2 receptor has a salt bridge between Lys109 and Asp275 in the CB2 EC-3 loop. 
3. Aromatic stacking interaction between toggle switch, which is crucial for G-protein activation. 
Phe200 and Trp358 are proposed as CB1 Toggle switch residues while Phe117 and Trp258 are 
considered as CB2 Toggle switch residues (102, 103). 
Molecular modeling (102, 104) in agreement with experimental site-specific mutational 
studies, which have suggested that Lys192 and Ser383 on TM3 play a critical role in ligand 
binding at the CB1 receptor, while Ser285 and Trp194 has an important role for the CB2 activity 
(105). The following residues are considered important for aromatic stacking for CB1: Phe170, 
Phe200, Phe208, Tyr215, Phe289, Tyr292, Tyr296, Trp356, and Phe379 (106-108). In regard to 
the CB2 receptor, the following residues are considered important for ligand binding: Lys109, 
Ser112, Phe117, Tyr190, Trp194, Phe197, Tyr258, and Ser285 (105, 106).  
1.1.13. Signaling of the cannabinoid receptors 
CB1 and CB2 receptors are experimentally known to couple with the pertussis toxin-
sensitive inhibitory G-protein (Gi) (109). The activation of these inhibitory G-proteins by CB1 
and CB2 agonists leads to the inhibition of adenylate cyclase and the cAMP pathway (110), 
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which ultimately inhibits the activation of cAMP-dependent protein kinase (PKA). This 
inhibition reduced the PKA phosphorylation and leads to an enhanced outward potassium current 
(111). In addition, CB1 activation also inhibits N- and P/Q-type voltage-dependent Ca2+ channels 
(111). CB1 receptor activation also results in transient increase of intracellular free Ca2+. These 
findings suggest that cannabinoids can suppress neuronal excitability and play a key role in 
regulating neurotransmitter release (111). In addition, CB1 and CB2 receptors both are able to 
activate mitogen-activated protein kinases-1 and -2, including extracellular signal-regulated 
kinase-1 and -2, and c-Jun N-terminal kinase (112-114). The CB1 receptor can also interact with 
other proteins through G protein-independent pathways such as β-arrestins, adaptor protein AP-
3, and the adaptor protein FAN to control receptor signaling or trafficking pathway (115).  
CB2 receptors are present in immune cells and modulate cytokine release, therefore; 
activation of B- and T-cell CB2 receptors by cannabinoids leads to the inhibition of adenylyl 
cyclase and a reduced response to immune challenge. Finally, CB2 receptor stimulation is also 
involved in the activation of serine/threonine-protein kinases such as protein kinase B that are 
involved in stimulating cell survival, migration and growth (116, 117). 
1.1.14. Retrograde signaling of cannabinoids 
Retrograde signaling of endocannabinoids (Figure 1.11) provides rapid feedback from a 
postsynaptic cell to its presynaptic inputs. Endocannabinoids like 2-AG can act as retrograde 
messengers at neuronal synapses in the central nervous system and regulate cannabinoid 
signaling in the brain. Either calcium-dependent or receptor-mediated signaling activates 
phospholipase C, which, in turn, leads to the formation and release of endocannabinoids like 2-
AG through post-synaptic neurons. These highly lipophilic signaling molecules further diffuse 
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across a chemical synapse to nearby presynaptic axon terminals where they bind to CB1 receptor 
and modulate signaling by reducing the release of inhibitory neurotransmitter gamma-
aminobutyric acid (GABA) and, in some cases, reduce the release of the stimulating glutamate 
neurotransmitters (118). This phenomenon, explained the physiological role of endocannabinoids 
by which neurons can rapidly regulate the strength of their synaptic inputs. Overproduction or 
excessive intake of endocannabinoids leads to inhibition of glutamate signaling, which may 
impair learning and memory. 2-AG is inactivated by MAGL and FAAH2 while AEA is degraded 
by FAAH2 only (119-121). 
 
 
 
 
 
 
 
Figure 1.11. Retrograde signaling by the endocannabinoid 2-AG at the neuronal synapse. This 
image has been reproduced with permission of Cayman Chemical and was retrieved from 
www.caymanchem.com. 
1.1.15. Tetrad assay 
The mouse tetrad assay was mainly developed to observe cannabimimetic-like action 
exerted by Δ9-THC. The test is also known as the Billy Martin test after the Professor who 
discovered the response (122). It refers a set of four behavioral assays that characterize 
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cannabimimetic effects, such as locomotor activity, catalepsy, body temperature, and 
nociception. The neurobehavioral effects of Δ9-THC in the mouse tetrad assay are well 
established and are typically referred to as classical cannabimimetic action. Δ9-THC acts as 
partial agonist in CB1 receptor and showed a reduction in the locomotor activity, and increases 
in catalepsy, hypothermia, and antinociceptive effects (123, 124). 
Locomotor activity or spontaneous activity: It is measured automatically by placing a mouse 
in an activity chamber during a 30-min period. This device calculates the number of times when 
mouse intercepts a photocell beam.  
Catalepsy: It is determined using a ring immobility apparatus. The mouse is placed on a bar and 
the time when it does not move is measured.  
Hypothermia: Body temperature is measured by digital rectal probe. 
Antinociceptive effects: Tail-flick latency (maximum 15 second to avoid tissue damage) is a 
measure of analgesia; the mouse’s tail is placed in a hot water bath (52 °C) and the time is 
recorded when it remove its tail from the water. At present, the radiant tail flick and hot plate 
methods are the best choice for studying antinociceptive effects. 
1.1.16. Allosteric modulators of CB1 
Several GPCRs have been shown to contain allosteric binding sites for 
endogenous/synthetic ligands, which are distinct from the agonist-binding (orthosteric) site. The 
binding of allosteric modulators leads to a conformational change of the receptor, which affects 
the affinity and/or efficacy of the orthosteric (endogenous) ligands, thereby provide strong 
mediator to modulate signaling pathway. The CB1 selective allosteric modulators include both 
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positive allosteric modulator (PAM) and negative allosteric modulator (NAM) (Figure 1.12). 
Allosteric modulators (AMs) exhibit distinct therapeutic advantages over orthosteric ligands in 
terms of enhanced target specificity and reduced off-target side effects (125-127). 
Organon research identified the first CB1 allosteric modulator as ORG 27569 and 
subsequently they synthesized series of ORG compounds such as ORG29647, and ORG27759 
(Figure 1.12). These all ORG compounds are known to be CB1 allosteric modulators (128, 129). 
Computational receptor modeling suggested that the ORG27569 binding site is located in the 
TMH3-6-7 region of the CB1 receptor, which is partially overlapped by the SR141716A binding 
site but extending extracellularly (130). Computational results suggest that Lys192 is part of the 
ORG27569 binding site, while Phe200 and Trp356 are not. Experimental results suggest that 
alone this compound can act as an agonist, in untreated and PTX-treated cells by increasing 
cAMP production. Computational modeling also suggested that ORG27569’s most important 
interaction is with residue Phe379; this is likely because ORG27569 forms several aromatic 
stacking interactions with Phe379. Together, these aromatic interactions help position 
ORG27569 in the receptor, placing a significant amount of ORG27569’s steric bulk against the 
EC end of TMH6 (130). PSNCBAM-1 (Figure 1.12) is another CB1 allosteric modulator, which 
behaves as a positive modulation of agonist binding. At up to 10 µM, PSNCBAM-1 had no 
effect on constitutive activity, which indicates that it does not act as an inverse agonist (131). 
Lipoxin A4 (LXA4) (Figure 1.12) is a positive allosteric endocannabinoid of CB1 receptors 
(132). This compound can cross the blood-brain barrier and displace the in vivo binding of [125I]-
RTI-55 in rat caudate, and it antagonizes the locomotor effects of cocaine (132). RTI-371 (Figure 
1.12) and other dopamine transporter inhibitors with a similar in vitro and in vivo 
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pharmacological profile were shown to be positive allosteric modulators of the human CB1 
receptor (133).	  
Considering the current major obstacles in cannabinoid-based drug discovery such as on- 
and off-target side effects associated with CB1 receptor in the CNS, the development of its 
allosteric modulators can avoid such side effects because of the distinct therapeutic properties of 
allosteric modulators in terms of receptor-selectivity and signaling-pathway-selectivity. 
However, detailed structural data on cellular pathways of 7-TMRs is still limited. Hence, 
computational methods play an important role for structural predictions of 7-TMRs as well as 
their binding to ligands.  
	  
 
 
 
 
 
 
 
Figure 1.12. Representative allosteric modulators of the CB1 receptor. 
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1.1.17. CB2 allosteric modulators 
The CB2 receptor may be a useful target for treating human diseases such as pain, 
inflammation, amyotrophic lateral sclerosis (ALS), cancer, ischemic/reperfusion injury, and 
osteoporosis; however, prolonged activation of the CB2 receptor may cause immunosuppression 
and bone loss (89, 134, 135). To date, only a few AMs of the CB2 receptor have been identified 
with micromolar activity, and there is insufficient knowledge of allosteric site(s) within the CB2 
receptor for efficiently targeted searches for new potent AMs. Recently, Maheshwari et al. 
(2011) reported trans-β-caryophyllene (TBC) as a highly selective dietary CB2 cannabinoid with 
unique ago-allosteric (compound that have an agonist property in the absence of orthosteric 
ligand as well as allosteric properties) characteristic by applying in vitro and in vivo experiments. 
From their studies, they suggested that TBC might function as a negative ago-allosteric 
modulator with a Ki (binding affinity) of 2.37 µM in a probe dependent manner (Figure 1.13) 
(136). 
 
 
 
 
 
 
 
 
 
Figure 1.13. Trans-β-caryophyllene (TBC) 
 
Dihydro-gambogic acid (DHGA), a derivative of gambogic acid has shown negative AM 
(Figure 1.14) effects on the CB2 receptor in a probe-dependent manner and was reported by 
Maheshwari et al. (2011) (136). 
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Figure 1.14. Structures of R (left) and S (right) isomers of dihydrogambogic acid. 
1.1.18. Research plan 
The primary goals of the studies in this dissertation were 1) to understand the putative 
binding interactions of cannabis-derived ligands with CB receptors; 2) to identify new CB1 
antagonists/inverse agonists using structure-based virtual screening; 3) to identify and 
characterize CB2 allosteric site(s) using known CB2 negative allosteric modulators and to 
identify new CB2 allosteric modulators with high affinity and selectivity. Based on the above-
mentioned goals, the research work was accomplished as reported in the following chapters: 
Chapter 2. To perform computational studies towards elucidation of the structure-activity 
relationship for Cannabis-derived and other natural products as cannabinoid receptor 
modulators 
A. To build and validate computational protein models of CB1 and CB2 receptors using 
an in silico modeling approach. 
B. To predict the binding modes of Cannabis-derived and other natural products with 
known activity on CB1 and CB2 receptors. 
C. To gain proper understanding of the key structural requirements from chapter 2B, and 
to design novel compounds with potential CB1 and CB2 activity. 
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Chapter 3. To identify novel natural product chemotypes as CB receptor modulators using 
protein structure-based virtual screening (SBVS) 
A. To carry out SBVS of the Zinc subset of natural products against the CB1 receptor. 
B. To determine the in vitro biological activity of the top ranked-hits (from chapter 3A) 
against CB1 and CB2 receptors using radioligand binding and GTPγS functional 
assays. 
C. To execute computational hit-to-lead optimization studies considering the best potent 
hits from chapter 3B, and further in vitro CB testing. 
Chapter 4. To identify and characterize allosteric site(s) within the cannabinoid CB2 
receptor, and to discover new CB2 allosteric modulators 
A. To identify allosteric site(s) within CB2 receptor using the SiteMap module of 
Schrödinger suite. 
B. To perform docking of dihydrogambogic acid (DHGA) and trans-β-caryophyllene 
(TBC) in the predicted allosteric site from chapter 4A. 
C. To carry out molecular dynamics (MD) simulation studies on the CB2–CP 55,940 
complex, and of complexes with dihydrogambogic acid (DHGA) and trans-β-
caryophyllene (TBC) with CB2–CP 55,940 already bound with CB2 receptor. 
D. To identify new CB2 allosteric modulators through SBVS using the allosteric 
modulator-optimized complexes from chapter 4C. 
E. To carry out in vitro testing of top ranked hits from chapter 4D against the CB2 
receptor, using radioactive binding and GTPγS functional assays. 
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CHAPTER 2 
 
 
 
 
 
 
Cannabis-Derived Compounds as Cannabinoid Receptor 
Modulators: Systematic Analysis Using Molecular Docking and 
Binding Free-Energy Studies 
 
 
 
Part of this chapter will be submitted for publication: Pandey, P., Roy, K. K., Doerksen, J. R. 
Cannabis-derived compounds as cannabinoid receptor modulators: Molecular docking and 
binding free-energy studies.
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2.1. Introduction 
The endocannabinoid system represents the group of cannabinoid (CB) receptors, 
transporters, endocannabinoids, and the endocannabinoid-degrading enzymes such as fatty acid 
amidohydrolase and monoacylglycerol lipase (24, 137-140). The diverse therapeutic potential of 
CB receptor agonists (141, 142) and antagonists (143, 144) has generated intense interest in 
researchers to explore the structural features of CB receptors which could explain their function, 
and that could be used in design of CB modulators. Cannabinoids are phenolic compounds 
belonging to the C-21 terpenophenolic chemical class, found in Cannabis sativa. The most 
specific and well-studied compound of this class is Δ9-tetrahydrocannabinol (Δ9-THC). The CB 
receptors (109) are classified into two subtypes: CB1, which is predominately expressed in the 
central nervous system (CNS), (22, 145) and CB2, predominately found in the immune system 
(146).  
Cannabis, also known as marijuana, is one of the oldest and most famous medicinal plant 
and has been used to treat various pathophysiological conditions such as arthritis, Glaucoma, 
inflammation, cancer etc. (45, 147, 148). To date, at least 111 cannabinoids have been identified 
from the Cannabis plant among which Δ9-THC represents the most psychoactive constituent (41, 
44, 149). The non-cannabinoids isolated from cannabis plants are flavonoids, spiroindans, 
dihydrostilbenes, sterols, alkaloids and other constituents (149). Over the last few decades, major 
computational research in the cannabinoid field has focused on selected natural and synthetic CB 
ligands such as Δ9-THC (150-153), AMG-3 (154), CP 55,940 (153, 155), HU-210 (155, 156), 
WIN55, 212-2 (150, 155), SR141,716 (157), HU-308 (156), and other endocannabinoids (150, 
158) in order to understand their target binding site(s), structural requirements and interaction 
patterns with the CB1 and CB2 receptor. However, no detailed understanding is available of the 
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rationale behind the experimentally observed wide variations in CB modulatory activities, in 
terms of affinity as well as specificity, with representative wide classes of natural compounds 
derived from cannabis. To the best of our knowledge, we report the first systematic 
computational study conducted on a set of cannabis-derived compounds in order to understand 
their interaction pattern and observed structure-activity relationship (SAR). We studied 25 
cannabinoids using molecular docking and binding free-energy calculations. For this, we used 
our in house constructed computational protein models of the CB1 and CB2 receptors. We 
believe that computational insights gained in this study could provide a platform to various 
medicinal chemists working in this important area of cannabinoid research, for the design and 
synthesis of new analogs of cannabis-derived compounds. This could in turn lead to the 
identification of new semi-synthetic or synthetic compounds with improved affinity and 
selectivity for CB receptors. 
2.2. Computational methods 
2.2.1. Modeling a set of Cannabis-derived compounds 
 
Three-dimensional (3D) structures of 25 compounds (1-25; Figure 2.1) with known 
activity (41, 44) (Table 2.1) against CB1 and CB2 were sketched in Maestro (159) and further 
minimized using the LigPrep (160) protocol of the Schrödinger suite. Compound 17 with two 
undefined stereocenters (the points of attachment of the epoxy ring) resulted in a total of four 
stereoisomers that were considered for docking analysis. Meanwhile, a total of 23 compounds 
(Compounds 1-16 and 18, 19 and 21-25) with observed good-to-high binding affinities (Ki) (~ 
11.0 nM to 8681.0 nM) and selectivity toward either of the two CB receptors were selected for 
analysis of their docking and binding free-energy calculation results in order to find explanations 
for the observed structure-activity relationships and to elucidate important structural features 
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vital for their CB binding affinity and selectivity. In order to facilitate results analysis and 
discussion with a view to improving readability, the 25 ligands were structurally classified into 
the following categories: (i) Δ9-THC and related analogs, compounds 1-8; (ii) Δ8-THC and 
related analogs, compounds 9-11; (iii) cannabinol and related analogs, compounds 12-14; (iv) 
cannabigerol and related analogs, compounds 15-19; (v) cannabichromanone and related 
analogs, compounds 21-23; and (vi) cannabidiol and related analogs, compounds 24-25. Figure 
2.2 shows the structures and numbering system assigned for the prototypic compounds assigned 
in each of the six categories.  
2.2.2. CB receptor models and receptor grid generation 
We used in house developed and validated computational models of the human CB1 and 
CB2 receptors. One of the models is already published (119). The in house prepared and 
validated three-dimensional (3D) homology models (unpublished results) representing a nearby 
active state (R*) of the CB receptor which matched with various active state features reported in 
the literature (161) based on the X-ray structures of other class-A GPCRs. Further, these models 
were used to study the putative binding mode(s) of the cannabis-derived compounds. The in 
house developed models of the human CB1 and CB2 receptors were validated through known 
active and inactive CB ligands. The docking receptor grids for the CB models were generated 
using the centroid of important residues lining the binding sites. In case of CB1 receptor grid 
generation, amino acid residues Asp3666.58, Lys1923.28, Phe1702.57, Phe1893.25, Phe2003.36, 
Trp2795.43, and Trp3566.48 were used (104, 107, 108). For the CB2 receptor grid generation, 
amino acid residues Lys1093.28, Ser1123.31, Ser2857.39, Trp1945.43, Trp2586.48, and Tyr1905.39  
were used (105, 106). 
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2.2.3. Molecular docking and scoring 
We used the Glide (162) flexible ligand docking protocol with the standard precision 
(SP) method. The energy-minimized ligands were docked into the receptor grids of the in house 
developed protein models of the human CB1 and CB2 receptors without using any constraint. A 
total of 10 distinct poses (root mean square deviation ≥ 0.5) were generated for each ligand 
wherever possible, in the docking with either of the two CB receptor models. Selection of the 
best pose for each ligand was made on the basis of computed values of Emodel and docking 
score. 
2.2.4. Binding free energy calculations 
The Prime Molecular Mechanics/Generalized Born Surface Area (MM-GBSA) (163) 
method was used to calculate binding free energies of the receptor and ligand using Prime 
Energy, molecular mechanics (force fields) and the continuum (implicit) solvation energy 
function (kcal/mol). In the present study, the binding free energies of the best poses of each 
ligand bound to the CB1 and CB2 receptors were calculated using the OPLS2005 (optimized 
potentials for liquid simulations) force field in a gas phase system and flexibility was limited to 
protein side chain sampling which was allowed to be for a region 5 Å around the bound ligand. 
The prime MM-GBSA tool uses the following formula to calculate the binding free energy (ΔG):  
MM-GBSA ΔGbind = Prime Energy (Optimized Complex) – Prime Energy (Optimized Free 
Ligand) – Prime Energy (Optimized Free Receptor). 
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Figure 2.1. Chemical structures of the 25 compounds considered in this study.	  
	  
	   41	  
O
H
H 1
36
7
9
O
H
H
O
1
9
3
H
H
OH
HO
OH
HO
O
OH
1
3
OO
O
H
6
Cannabinol
1
35
6
7
4
89 10
1
3 5
Cannabidiol
Δ9−THC Δ8−THC
8
3
1
6
Cannabigerol Cannabichromanone C
6
7 8
OH OH OH
 
Figure 2.2. Numbering system for representative compounds from each of the six categories. 
2.3. Results and discussion 
Knowledge of the CB pharmacophores, the necessary structural features associated with 
CB receptor binding and cannabimimetic activities, has evolved based on structure-activity 
studies on a large set of diverse structures. This resulted from the efforts of natural products 
chemists and medicinal chemists over many decades (164, 165). The evolved consensus 
observation is focused on three main structural components for cannabis-derived compounds, 
and also for non-classical cannabinoids. The three main structural components are: (i) an 
extended aliphatic side chain (C3-C7) at the meta-position of the phenol, (ii) a phenolic hydroxyl 
group, and (iii) a favorable conformation of ring-C stabilized by a suitable substituent at the C-9 
position. In the past, these three main components have been coded as the three-point 
pharmacophore model for CB receptor binding that has been correlated with the inhibition of 
adenylate cyclase (166). Considering this three-point model, further medicinal chemistry efforts 
of synthesizing and testing various non-classical analogs led to the foundation of a fourth main 
structural component called a southern aliphatic hydroxyl that enhances CB activity (167). From 
the known SAR, it was observed that all of these structural features are not absolutely required, 
but they contribute collectively or in some combination to enhance CB activity. 
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2.3.1.1. Aromaticity and planarity of ring-A 
Extensive efforts over many decades including biological testing of various classical 
cannabinoids isolated from the marijuana plant and non-classical cannabinoids resulting from 
various synthetic modifications of THC has led to discovery of the importance of aromaticity as 
one of the structural requirements for cannabimimetic activity and binding with the CB receptors 
(168). The results from our docking study well demonstrated that the aromaticity of ring-A is 
required for strong hydrophobic π–π stacking with aromatic amino acid residues forming the 
deep binding pocket of the CB1 and CB2 receptors. For the CB1 receptor, these amino acid 
residues are Phe170 and Trp279, which are located near ring-A of the docked potent compounds 
(representative compounds from each class: 1, 9, 12, 15, 21, 24) (Figure 2.3A). Nevertheless, 
Trp194 of the CB2 receptor adapts to and stabilizes the bound ligand through π–π and CH- π 
stacking interactions with the aromatic ring-A component (Figure 2.3B). In both of the CB 
receptor subtypes, these aromatic residues are part of the 
deep binding pocket necessary for efficient ligand binding. 
 
Figure 2.3. Overlay of representative structures of each class depicting a strong hydrophobic π–π 
stacking of ring A with Trp279 and Phe170 of the CB1 receptor (A), and with Trp194 of the 
CB2 receptor (B) (represented as cartoon). Compounds 1 (carbon in green), 9 (carbon in cyan), 
A	  
B	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12 (carbon in white grey), 15 (carbon in magenta), 21 (carbon in yellow), 24 (carbon in wheat) 
are shown. Selected amino acids are shown in gray-colored carbons. 
2.3.1.2. Phenolic hydroxyl group of ring-A 
The phenolic hydroxyl group at the C-1 position of ring-A has an important role for the 
CB activity. Previous studies (169, 170) have shown that the replacement of the phenolic 
hydroxyl group in THC analogs with methyl, methoxy, carboxyl, thiol and hydrogen 
significantly decrease the CB1 activity. Our docking study revealed the importance of the 
hydroxyl group. The C-1 hydroxyl group present in compounds 1 (CB1 Ki= 18±4 nM and CB2 
Ki= 42±9 nM; CB2, ΔGbind = −102.579 kcal/mol) and 9 (CB1 Ki= 78±5 nM and CB2 Ki= 12±2 
nM; CB2, ΔGbind = −109.721 kcal/mol) exhibited H-bonding with Val261 (CB2) that was 
stabilized by the π-π stacking interaction with Trp194 (Figure 2.4A). Docking with the CB1 
receptor, compound 1 and 9 revealed H-bonding with Lys192 via the C-1 hydroxyl group, which 
is the key interacting residue for the CB1 activity. The endocyclic pyran oxygen of compound 1 
and 9 also form H-bond with Ser383 (Figure 2.4B).  
Figure 2.4. 3D interactions diagram of compound 1 (Carbons in green) and 9 (carbons in cyan) 
depicting H-bonding of phenolic OH of ring A with Val261 of the CB2 receptor (A) and Lys192 
in the CB1 receptor (B) (represented as cartoon). H-bonds are shown as black-colored dashed 
lines. Selected amino acids are shown in gray-colored carbons. 
A	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In contrast, the compound 2 (CB1 Ki= 1292±89 nM and CB2 Ki= 1650±163 nM) 
comprising a C-1 carboxyl group lacked any H-bonding with the CB1 (Lys192 and Ser383) and 
CB2 receptors (Figure 2.5A and 2.5B). This may be the reason why this compound showed 
lesser affinity compared to compounds 1 and 3. It further substantiates our observation of the 
particular importance of C-1 hydroxyl group for the CB activity.  
 
Figure 2.5. 3D interaction diagram of compound 2 (Carbon in yellow) with the CB1 receptor  
(A) and with CB2 receptor (B) (represented as cartoon). H-bonds are shown as black-colored 
dashed lines. Selected amino acids are shown in gray-colored carbons. 
2.3.1.3. Extended side chain(s) at C-3 position of ring-A 
Previous work by several research groups focused on synthetic modifications of THC, 
including Adam’s work in the 1940s, (171) and Edery’s work in 1972 (172). They demonstrated 
an optimal requirement of an extended linear or branched side chain (5-7 carbons) at the C-3 
position of the phenol (or ring-A). In the present docking study, the five-carbon side chain at the 
C-3 position of ring-A, (representative compounds from each class: 1, 9, 12, 15, 21, 24) 
	  A	   	  B	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displayed better binding with either of the CB receptors (Figure 2.6A and 2.6B) than compounds 
comprising three-carbon side chain (see compounds 3, 14, 25) (Figure 2.7A and 2.7B). 
Compound 3 displayed identical H-bonding and π-π interaction patterns to 1 at the binding site 
of CB1 and CB2 receptors.  
 
 
 
 
 
 
 
 
 
Figure 2.6. Surface mapping of compounds 1 (carbon in green), 9 (carbon in cyan), 12 (carbon 
in white grey), 15 (carbon in magenta), 21 (carbon in yellow) and 24 (carbon in wheat) 
containing five-carbon chain at C-3 position docked with the CB1 receptor (A) and with the 
CB2 receptor (B).  
 
However, 3, possessing a comparatively shorter side chain at the C-3 position, showed lower 
affinity in terms of docking score (weaker hydrophobic interaction) and experimental Ki values 
compared to compound 1 in both CB receptors (Figure 2.8A and 2.8B) 
	   	  A 	  B 
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Figure 2.7. Surface mapping of compounds 1 (carbon in green), 9 (carbon in cyan), 12 (carbon 
in white grey), 15 (carbon in magenta), 21 (carbon in yellow) and 24 (carbon in wheat) 
containing three carbon chain at C-3 position docked with the CB1 receptor (A) and with the 
CB2 receptor (B).  
2.3.1.4. Importance of pyran ring (ring-B) 
 The intact benzopyran ring system in THC and its analogs is apparently necessary to 
exhibit CB activity. The opening or expansion of the pyran ring may interfere with the alignment 
of the remaining two rings (A and C) leading to the complete loss of CB activity. However, the 
non-classical cannabinoids such as CP-55,940, which lacks the ABC tricyclic benzopyran 
substructure of the classical cannabinoids, still fulfill the structural requirements for 
cannabimimetic response and exhibit a good CB activity (173, 174). The benzopyan ring should 
be intact with either nonplanar acyclic ring-C or with ring-A for CB activities. Our docking 
results on compounds 15-20 (Table 1), which lacks pyran ring also showed poor docking scores 
against the CB1 receptor, however these compounds showed slightly higher docking scores 
against the CB2 receptor. 
 
A	   B	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Figure 2.8. Surface mapping of compounds 1 (carbon in green) and 3 (carbon in light wheat) 
containing five and three carbon chains, respectively, at C-3 position docked with the CB1 
receptor (A) and CB2 receptor (B) (represented as cartoon). H-bonds are shown as black-colored 
dashed lines. Selected amino acids are shown in gray-colored carbons. Protein surface is shown. 
 
Among these studied compounds, docking scores well correlated with the experimental affinity 
(Ki, nM). Compounds 24 and 25, (Figure 2.16 A-D) lacking the pyran ring system similar to CP-
55940, still fulfill the structural requirement for cannabimimetic response due to presence of 
hydroxyl group that behaved as H-bond acceptor/donor (for more details, please see section 
‘Cannabidiol’). 
2.3.1.5. Impact of the alicyclic ring-C substituents on CB binding affinity 
 11-hydroxy-THC (175), a THC metabolite, or a keto group at the C-9 (as in Nabilone 
(176), a synthetic cannabinoid) position enhanced CB activity. The methyl group at the C-9 
position in Δ8- and Δ9-THC exhibits comparable binding affinities towards CB receptors. The 
previous computational studies have shown that the C-9 methyl in Δ9-THC improves activity 
A	   B	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when it is in the beta orientation, but in the alpha-orientation, it becomes inactive (177). The 
presence of the hydroxyl group at C-8 (an S-position) such as in 8-hydroxy-THCs, also affords 
the retaining of activity. Planarity of the ring-C is not a necessary criterion for activity. 
The docking pose of compound 5 displayed an intra-molecular H-bonding between C-10 
α-OH and C-1 OH groups, which provided a favorable conformation to interact with a key 
residue Lys192 of the CB1 receptor via H-bonding with C-10 α–OH (Figure 2.9 A). This led to 
its high affinity towards the CB1 receptor. In contrast, the compound 6 lacked any intra-
molecular H-bonding between C-10 β-OH and C-1-OH groups, and the resulting conformation 
did not show any interaction with lys192, resulting into a poor binding affinity towards the CB1 
receptor (Figure 2.9 C). In the case of docking results of these compounds at the CB2 receptor, 5 
(Figure 2.9 B) displayed an intra-molecular H-bonding between C-10 α-OH and C-1 OH groups 
similar to its binding at CB1, and provided a stable conformation that simultaneously oriented in 
such a way within the CB2 binding site where C-1 OH formed H-bond with Val261 and the C-3 
alkyl chain exhibited strong hydrophobic interactions with several hydrophobic residues. 
Compound 6, possessing a β-hydroxy group at C-10 position, lacked any polar interactions and 
exhibited a poor docking score with CB2 (Figure 2.9 D). 
	   49	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. 3D interaction diagram of compound 5 (Carbon in cyan) and compound 6 (Carbon in 
yellow) with the CB1 receptor (A and C) and with the CB2 receptor (B and D) respectively, 
(represented as cartoon). H-bonds are shown as black-colored dashed lines. Selected amino acids 
are shown in gray-colored carbons. 
 
Similar to the compound 5, an intra-molecular H-bond between C-10 α-OH and C-1 OH groups 
in 10 provided a favorable conformation to simultaneously allow C-10 α–OH group to interact 
with Thr114 of the CB2 receptor via H-bonding (Figure 2.10 B). Meanwhile, at the CB1 binding 
site, 10, with an intra-hydrogen bonding between C-10 α-OH and C-1 OH groups attained a 
favorable conformation and exhibited H-bonding between C-10 α-OH and Lys192 (Figure 2.10 
A). 
A	   B	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Compound 11, similar to 6 lacking an intra-molecular H-bonding due to the presence of C-10 β-
OH group, lacked any indirect/direct electrostatic interactions with a key CB1 residue Lys192 
(Figure 2.10 C), however, it exhibited H-bonding with Thr114 and π-π stacking interaction with 
Trp194 residue of the CB2 receptor (Figure 2.10 D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. 3D interaction diagram of compound 10 (Carbon in cyan) and compound 11 
(Carbon in yellow) with the CB1 receptor (A and C) and with the CB2 receptor (B and D) 
respectively, (represented as cartoon). H-bonds are shown as black-colored dashed lines. 
Selected amino acids are shown in gray-colored carbons. 
 
Compound 7 with α-OH at C-8 position functionality attained a binding pose where the α-OH 
formed H-bond with Lys192 and endocyclic pyran oxygen with Ser383 but lacked a strong 
hydrophobic interaction with Phe174. In contrary, the presence of a β-OH at C-8 position (Ring-
A B 
C D 
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C) of compound 8, resulted into a favorable conformation, where rings A and C exhibited strong 
hydrophobic interaction with Trp279 and Phe174 of CB1, respectively (Figure 2.11 A and 
2.11B). In addition, a β-OH at C-8 position of compound 8 showed H-bonding with His178. 
Compound 8 also possesses a similar H-bond with an endocyclic pyran oxygen via Ser383. At 
CB2, 7 did not show H-bonding with Thr173, while 8 showed polar interaction with Thr173 and 
Val261 via its C-8 β-OH and C-1 OH groups, respectively (Figure 2.12). 
 
 
 
 
 
 
 
 
 
Figure 2.11. 3D interaction diagram of compound 7 (Carbon in cyan) and compound 8 (Carbon 
in yellow) with the CB1 receptor (A and B) respectively (Represented as cartoon). H-bonds are 
shown as black-colored dashed lines. Selected amino acids are shown in gray-colored carbons. 
2.3.2. Cannabinol (CBN) 
The high binding affinity for the CB2 receptor was observed when the hydroxyl group 
was present at C-1 in the Cannabinol series (178), however removal of this group in the THC 
series of compounds significantly reduced the binding affinity for the CB1 compared to CB2. 
The C-3 alkyl side chain modification has no significant impact when the hydroxyl group is 
present at C-11 of the 1-deoxyy CBN series. In general, we can say that the presence of the 
hydroxyl group either in ring-A or ring-C plays an important role for enhancing CB2 binding  
	  A	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Figure 2.12. 3D interaction diagram of compound 7 (Carbon in cyan) and compound 8 (Carbon 
in yellow) with the CB2 receptor (represented as cartoon). H-bonds are shown as black-colored 
dashed lines. Selected amino acids are shown in gray-colored carbons. 
 
affinity. The docked pose of the most active compound 13 (CB2 Ki = 11 nM) in the CBN series, 
showed the two hydroxyl groups at positions 1 and 8 exhibited H-bond interactions with Val261 
and Thr173, respectively of the CB2 receptor. Meanwhile, it was further stabilized through 
strong hydrophobic interactions with several residues lining the binding site, mainly via π-π 
stacking interactions	   with	   Trp194	   and	   Phe117	   residues	   (Figure	   2.13	   B). In contrast, this 
compound docked in the CB1 model exhibited H-bonding between endocyclic pyran oxygen and 
Ser383, and the π-π stacking interaction with Trp279 residue. However, it lacked the H-bonding 
interaction between C8-OH and any of the CB1 binding site residues.  Specifically, an absence 
of H-bond interaction with key residue Lys192 could be the main reason for its poor binding 
with CB1, and hence low CB1 binding affinity (Figure 2.13 A).	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Figure 2.13. 3D interaction diagram of compound 13 with the CB1 (A) and CB2 (B) receptor 
(represented as cartoon). H-bonds are shown as black-colored dashed lines. Selected amino acids 
are shown in gray-colored carbons.  
 
 
Figure 2.14. 3D interaction diagram of compound 12 with the CB1 (A) and CB2 (B) receptor 
(represented as cartoon). H-bonds are shown as black-colored dashed lines. Selected amino acids 
are shown in gray-colored carbons. 
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Compound 12, lacking OH group at C-8 position present in 13, showed comparatively a poor 
binding with CB2 which is in good agreement with our docking analysis. It may be due to the 
absence of H-bonding interaction with a key residue Thr173 of CB2 model that was observed 
with the docking pose of compound 13 (Figure 2.14 B). 
 On the other hand, 12 showed a better binding affinity with CB1 receptor. Docking study 
revealed that the lack of OH group at C-8 position helped 12 to bind more favorably by 
exhibiting strong hydrophobic interactions with CB1 residues lining the binding site. The methyl 
group at C-7 position of 12 was stacked between Phe174 and Phe177 residues of CB1 that was 
disfavored in compound 13 due to C-8 OH group (Figure 2.14 A). Compound 14 docked at the 
CB2 receptor exhibited π-π stacking with aromatic residues Trp194 and Phe117, and also 
engaged in the H-bond formation with Val261. Being the C-3 alkyl chain shorter in 14 (propyl) 
than compounds 12 (pentyl) and 13 (pentyl), it did not fit tightly in the hydrophobic pocket of the 
CB2 receptor, and therefore showed a comparatively lower CB2 affinity. In the case of the CB1 
receptor, the pyran oxygen of 14 displayed strong H-bond with Ser383, and ring-C exhibited π-π 
stacking interaction with Phe177. Meanwhile, the C-1 OH and Lys192 were located in 
considerably close proximity (4.392 Å) that can form an H-bond considering the aspect of the 
binding site flexibility. The C-3 propyl chain poorly interacted with hydrophobic residues of 
CB1, and thus affected the stability of the CB1 binding leading to an observed lower CB1 
affinity compared to the compound 12 (Figures 2.15 A and 2.15 B). Overlays of compounds 12, 
13 and 14 are shown with the CB1 (Figure 2.15 C) and CB2 (Figure 2.15 D) receptors. 
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Figure 2.15. 3D interaction diagram of compound 12 (carbon in yellow) with the CB1 (A) and 
CB2 (B) receptor (represented as cartoon). Overlay of compounds 12 (carbon in yellow), 13 
(carbon in cyan) and 14 (carbon in green) with the CB1 receptor (C) and with CB2 (D) 
(represented as cartoon) H-bonds are shown as black-colored dashed lines. Selected amino acids 
are shown in gray-colored carbons. 
 
2.3.3. Cannabidiol (CBD) 
Cannabidiol is the non-psychoactive constituent derived from the cannabis plant. Among 
enantiomers of CBD series of compounds including the synthetic dimethylheptyl CBD 
homologs,  (+) enantiomers exhibited significantly better CB1 activity in contrast to the (-)-
B	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enantiomers (179-181). The hydrogenated CBD series of compounds at the C-1 and C-8 
positions, exhibited good binding to the CB1 receptor (182). The (-)-cannabidiol exhibited much 
lower affinity than Δ9-THC toward either of CB receptors. Our docking and binding free-energy 
results explained the higher affinity of compound 24 (cannabidiol) and 25 (Cannabidiverin) 
towards CB1 than the CB2 receptor. Both of these compounds lack an intact benzopyran ring but 
still exhibits CB activity, thus indicating the low impact of the ring-B for CB binding and 
activity. The only difference between them is the length of alkyl chain at C-5ʹ′ position. Similar 
to other class of compounds such as Δ8-THC, Δ9-THC and CBN, the C-3ʹ′ hydroxyl group of 
compounds 24 and 25 displayed a strong H-bonding with Ser383 and exhibited π-π stacking 
interactions with Trp279 of the CB1 receptor. The C-5ʹ′ alkyl chain of 24 deeply interacted in the 
hydrophobic pockets of CB1 and exhibited strong hydrophobic interactions with several 
residues, including Leu193, Val196, Phe200, Met277, Phe278, Leu286, Trp356, and Met363 
lining the CB1 binding site. Such hydrophobic interaction was comparatively weaker in case of 
compound 25, comprising a shorter alkyl chain at the C-5ʹ′ position. In contrast, unlike Δ9-THC, 
these compounds didn’t show strong interactions with Lys192 (distance= 3.28 Å) that might be 
reason for their weaker CB1 affinity compared to Δ9-THC. In the case of CB2 receptor binding 
studies, the C-3ʹ′ hydroxy group of both of these compounds exhibited H-bonding with Val261 
and showed hydrophobic interactions with key residues, namely Phe117, Ala199 and Trp258. 
The experimentally observed lower CB2 binding affinity of these compounds compared to Δ9-
THC may be due to lack of π-π stacking interactions with Trp194, which is known to be a key 
residue for the CB2 activity (Figures 2.16 A-D). 
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Figure 2.16. 3D interaction diagram of compounds 24 (carbon in light wheat) and 25 (carbon in 
blue) with the CB1 receptor (A and B) and with the CB2 receptor (C and D) respectively 
(represented as cartoon). H-bonds are shown as black-colored dashed lines. Selected amino acids 
are shown in gray-colored carbons. 
2.3.4. Cannabigerol (CBG) 
CBG is a non-psychoactive cannabinoid obtained from the cannabis plant as a minor 
constituent, however it is found in higher concentrations in hemp strains. Cascio et al. (183) 
found that CBG has higher binding affinity towards CB1 than the CB2 receptor in in vitro 
studies, however, Gauson et al (184) and Pertwee et al (185) found these compounds to exhibit 
B	  A	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quite similar affinity towards both of the CB receptor subtypes. So far, little information is 
available in terms of understanding of the SAR among this class of compounds and thus we 
carried out docking studies on this class of compounds. 
The docking results of compounds 15-19 are in good agreement with the experimental 
results. Compounds 15 and 16 showed H-bonding with Ser383 and Lys192 via C-1 OH and C-1 
COOH groups, respectively, against the CB1 receptor (Figure 2.17 A and 2.17 B). They showed 
π-π stacking interactions with Trp279, and C2 and C-3 alkyl chain favorably resided and 
hydophobically stabilized in the deep CB1 pocket lined with residues, namely Trp356, Leu360, 
Leu287, Met277, Leu286, Val191, Phe278, Val196, Phe200 and Met363.  
 
 
 
 
 
 
 
Figure 2.17. 3D interaction diagram of compound 15 (carbon in magenta) and 16 (carbon in 
cyan) with the CB1 receptor (A and B) (represented as cartoon). H-bonds are shown as black-
colored dashed lines. Selected amino acids are shown in gray-colored carbons. 
 
Compound 16 exhibited H-bonding with Thr114 via C-1 COOH and C-2 OH groups, and 
showed π-π stacking interactions with Trp194 of the CB2 receptor (Figure 2.18 B), however, the 
C-6 alkyl chain could not penetrate deeply into the hydrophobic pocket lined by Trp258, Phe117, 
Leu195, Ile198, Phe202, Val121, and Met265, which may be due to the presence of C-1 COOH 
group causing steric hindrance and thus resulted into a poor CB2 affinity. In contrast, compound 
A	   B	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15 exhibited strong H-bonding with Val261 via C1-OH group, and C-5 alkyl chain deeply 
penetrated into the hydrophobic pocket of the CB2 receptor, and hence, 15 showed a better CB2 
binding affinity (Figure 2.18 A), than the compound 16.  
 
 
 
 
 
Figure 2.18. 3D interaction diagram of compound 15 (carbon in magenta) and 16 (carbon in 
cyan) with the CB2 receptor (A and B) (represented as cartoon). H-bonds are shown as black-
colored dashed lines. Selected amino acids are shown in gray-colored carbons. 
 
 
Compound 18 lacked H-bonding interactions with key CB1 residue, Lys192, resulted in a weak 
CB1 affinity, however, compound 19 displayed H-bonding interactions with CB1 residues 
Lys192 and Trp279 via C-5 acetoxy and C-4 OH groups, respectively. In addition the alkyl chain 
at C-6 position exhibited strong hydrophobic interactions with CB1 residues Phe200, Phe278, 
Trp279, Trp356, Val191 and Val196 (Figure 2.19 A and 2.19 B). With the CB2 receptor, 18 
displayed a strong H-bonding with Val261 via C-5 OH and π-π stacking interaction with Trp194, 
while 19 (Docking score = −8.525 and Binding energy = −104.618 kcal/mol) showed strong H-
A	   B	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bonding interactions with Thr114 and Val261 via C-5 acetoxy and C-1 OH groups, respectively. 
In addition, 19 exhibited π-π stacking interactions with Trp194, and strong hydrophobic 
interactions with Trp258, Phe202, Phe259, Ala199, and Leu262 residues of the CB2 receptor 
(Figure 2.19 C and 2.19 D).  
 
Figure 2.19. 3D interaction diagram of compounds 18 (carbon in green) and 19 (carbon in 
yellow) with the CB1 receptor (A and B) and with the CB2 receptor (C and D) respectively 
(represented as cartoon). H-bonds are shown as black-colored dashed lines. Selected amino acids 
are shown in gray-colored carbons. 
A	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Table 2.1. Summary of docking and binding free-energy results of compounds with CB1 and 
CB2 receptor models. 
 
 
Title 
Binding affinity 
(Ki, nM) 
Docking score Emodel value 
Binding  free-energy 
(ΔG, kcal/mol) 
 
CB1 CB2 CB1 CB2 CB1 CB2 CB1 CB2 
1 18±4 42±9 −8.755 −8.654 −55.792 −53.999 −99.722 −102.579 
2 1292±89 1650±163 −7.900 −7.978 −39.468 −59.085 −69.740 −76.824 
3 22±5 105±21 −8.595 −8.436 −50.383 −49.544 −84.781 −79.249 
4 5668±132 2143±353 −7.787 −7.896 −52.242 −49.214 −94.790 −87.534, 
5 117±16 129±13 −8.447 −8.655 −54.44 −54.367 −98.600 −92.52 
6 >10,000 >10000 −7.885 -6.557 −43.253 −47.043 −85.843 −78.857 
7 1906±578 3219±876 −8.328 −8.324 −51.816 −55.887 −94.506 −90.183 
8 65±16 88±19 −8.747 −8.357 −52.813 −54.35 -93.629 −104.548 
9 78±5 12±2 −8.649 −9.232 −55.151 −59.079 −100.753 −109.721 
10 31±6 30±4 −8.678 −7.715 −57.760 −49.593 −99.902 −77.452 
11 830±94 3274±515 −8.450 −7.587 −48.873 −51.189 −96.147 −95.283 
12 75±4 73±4 −8.362 −8.853 −49.739 −59.5106 −90.561 −89.286 
13 8063±198 11±1 −7.617 −9.830 −45.790 −67.864 −75.300 −103.401 
14 565±138 4780±331 −8.469 −7.872 −50.170 −47.897 −75.614 −69.101 
15 3090±583 2919±752 −7.648 −8.188 −59.975 −58.296 −99.496 −90.028 
16 4526±953 >10000 −7.581 −7.401 −57.970 −61.120 −85.831 −79.225 
17 >10,000 4718±87 
17_1 = −8.351 17_1 = −8.583 17_1 = −58.110 17_1 = −58.856 
ND ND 
17_2 = −8.066 17_2 = −8.292 17_2 = −58.989 17_2 = −58.251 
17_3 = −8.513 17_3 =−7.942 17_3 = −60.506 17_3 = −60.803 
17_4 = −8.222 17_4 = −8.409 17_4 = −57.510 17_4 = −62.079 
18 >10,000 3989±772 −7.277 −8.463 −48.3 −59.125 −84.419 −100.677 
19 1409±162 388±67 −7.635 −8.525 −30.745 −63.374 −82.839 −104.618 
20 >10,000 >10000 −6.554 −7.408 −51.539 −50.332 ND ND 
21 3470±601 4371±111 −8.807 −8.517 −59.605 −66.897 −90.09 −98.941 
22 8681±140 5789±685 −7.831 −8.288 −52.152 −65.997 −73.919 −97.768 
23 7117±109 2828±569 −7.535 −8.34 −30.584 −52.592 −78.601 −92.091 
24 151±28 4582±613 −8.285 −7.352 −27.931 −49.165 −73.731 −90.771 
25 503±58 3970±976 −8.531 −7.361 −42.883 −47.313 −59.672 −81.361 
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2.3.5. Cannabichromene (CBC) 
CBC and its related compounds are also found in significant quantity in the cannabis 
plant. Only a few studies (44, 186) have been done for pharmacological activities and to 
elucidate the SAR of this class of compounds. For cannabinoid activity, the attachment of a 
nonplanar alicyclic ring to the benzopyran ring is important. It is clear that the benzopyran ring 
itself is not responsible for the activity (168). Compound 21 displayed H-bonding with Lys192 
and Ser383 via its C-5 acetyl and β–Hydroxy groups, respectively, and exhibited π-π stacking 
interactions with Trp279 of the CB1 receptor. The C-3 alkyl chain showed hydrophobic 
interactions with CB1 residues Val196, Trp279, Met363, Phe278, Trp356, Phe200 and Cys356. 
Compound 22 exhibited H-bonding with Lys192 via 3-ketone of the pentane-3,4-diketone 
moiety but lacked H-bonding with Ser383 (ΔGbind = −73.919 kcal/mol) and exhibited π-π 
stacking interactions with Trp279 of the CB1 receptor.   
 
Figure 2.20. 3D interaction diagram of compounds 21 (carbon in yellow), 22 (carbon in cyan) 
and 23 (carbon in green) with the CB1 receptor (A, B and C) (represented as cartoon). H-bonds 
are shown as black-colored dashed lines. Selected amino acids are shown in gray-colored 
carbons. 
 
Compound 23 didn’t show H-bonding with Lys192 and Ser383, however, exhibited similar 
hydrophobic interactions as seen with compounds 21 (Figure 2.20 A and 2.20 B). This 
compound, however, lacked H-bond interactions with Lys192 and Ser383 and thus explaining 
the poor CB1 affinity (Figure 2.20 C). However, in the case of CB2, compound 23 displayed 
A B
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strong H-bonding with Thr114 and showed π-π stacking interactions with Trp194. The alkyl 
chain of 23 also exhibited strong hydrophobic interactions with several CB2 residues, including 
Trp258, Leu262, Phe259, Ile198, Phe202, Val261 and Phe117. Furthermore, these compounds, 
similar to 23, exhibited π-π stacking interactions with Trp194 and slightly weaker hydrophobic 
interactions with the CB2 receptor. However, the formation of an H-bonding with Thr114 and 
deeper penetration of the alkyl chain led the compound 23 as more potent than compounds 21 
and 22 against the CB2 receptor (Figure 2.21 A-C). 
 
 
Figure 2.21. 3D interaction diagram of compounds 21 (carbon in yellow), 22 (carbon in cyan) 
and 23 (carbon in green) with the CB2 receptor (A, B and C) (represented as cartoon). H-bonds 
are shown as black-colored dashed lines. Selected amino acids are shown in gray-colored 
carbons. 
2.4. Conclusion 
 The systematic computational protein-ligand interaction studies of cannabis-derived 
compounds using CB1 and CB2 receptor models revealed the importance of several key residues 
that are engaged in H-bonding, aromatic stacking and hydrophobic interactions with the ligand. 
We have used widely applied molecular docking and binding free-energy computation 
approaches to elucidate sets of key protein-ligand interactions that well explained the observed 
A B C 
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structure-activity relationship among the four series of cannabis-derived compounds. These 
studies of Δ9-THC and related compounds validate the experimental SAR studies of cannabis 
related compounds where importance of C-3 alkyl chain and C-1 substitutions were reported. 
Our docking study explained the role of C-8 hydroxyl group and C-3 alkyl chain length of 
cannabinol class of compounds for CB2 activity and selectivity. Furthermore, alpha and β-
hydroxyl substitutions at C-8 and C-10 positions of Δ9-THC and Δ8-THC related compounds 
exhibited important roles in terms of intra-hydrogen bonding for stabilization of ligand with 
receptor binding. The docking study also revealed the importance of the hydroxyl group in 
compounds 24 and 25, which lack the pyran ring system similar to CP 55,940, which can still 
fulfill the structural requirement for cannabimimetic response by behaving as H-bond 
donor/acceptor. The negative binding energy of compounds also verify the best poses with 
experimental activity that undertaken in discussion of the particular ligands. 
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CHAPTER 3 
 
 
 
 
 
 
Structure-Based Identification of Novel Natural Product Chemotypes as 
Cannabinoid Receptor Modulators 
 
 
 
 
 
 
 
 
 
Content of this chapter will be submitted for publication: Pankaj Pandey, Kuldeep K. Roy and 
Robert J. Doerksen. Structure-Based Identification of Novel Natural Product Chemotypes as 
Cannabinoid Receptor Modulators. 
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3.1. Introduction 
The cannabinoid (CB) receptors belong to the Class A, membrane-bound rhodopsin-like 
family of G-protein coupled receptors (GPCRs) and are characterized by seven transmembrane 
(TM) helices/domains (109, 187). One of the CB receptor subtypes, CB1, is especially abundant 
in the central nervous system (188); however, it is also found in peripheral tissues (73). Another 
subtype, CB2, is mostly present in the immune system and the spleen (23, 189); though recent 
evidence suggests that the CB2 receptor is also expressed in the CNS in small proportions (190). 
GPCRs represent the largest single group of targets for approximately 50% of FDA 
approved drugs. Functional selectivity among these targets is highly recommended for successful 
drug discovery (1, 191). CB1 receptor antagonists are clinically established to be effective in 
treating obesity (192), obesity-related cardio-metabolic disorders (193), and substance abuse 
(194, 195). The druggability of the CB1 receptor antagonists has been clinically validated 
through the drug rimonabant (196), which showed progressive and prolonged weight loss (197) 
and improvements in associated metabolic disorders (198, 199) in Phase III clinical trials. 
Unfortunately, due to unwanted CNS side effects associated with rimonabant such as depression, 
anxiety, nausea and dizziness, prescription of rimonabant is not authorized in the USA and 
recently was halted in Europe (59). On the other hand, the CB2 receptor is also an important 
target for the discovery of therapeutics for neuro-inflammation, cardio-metabolic disorder, 
cardiac-ischemia and other diseases/disorders (97, 200-202). 
A proper understanding of the CB receptor, potential binding pockets, and CB-ligand 
binding modes may assist the discovery of new potential therapeutics targeting CB receptors. 
Unfortunately, none of the CB receptor subtypes have been crystallized, nor have their three-
dimensional (3D) structures been experimentally characterized. In such a scenario, molecular 
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modeling tools have been useful for understanding the putative 3D structures of CB receptors, 
modes of protein-ligand interactions, and important physicochemical and structural requirements 
for effective CB modulation. In the search for novel molecules targeting the endocannabinoid 
system, past research efforts were devoted towards developing promising analogs or isosters of 
rimonabant (203-205) targeting the CB1 receptor, but none of the discovered compounds 
reached phase III clinical trials. Recent studies support the successful identification of drug-like 
sub-micro/nanomolar CB1 antagonists using bovine rhodopsin-based homology models (206, 
207) and pharmacophore modeling (208-210). 
Natural products continue to be a major source of new and structurally diverse leads. 
Natural product drug discovery outlines many important drugs that revolutionized the treatment 
of several diseases over several decades (164). In view of this, we embarked on a journey to 
discover new natural product chemotypes as CB modulators, which is described in this paper. 
We utilized a protein structure-based virtual screening (SBVS) approach from the all purchasable 
Zinc subset of the natural products database (211). 
3.2. Computational Methods  
3.2.1. Protein preparation, receptor grid generation and amino acid numbering system 
The 3D coordinates of our recently reported antagonist-bound CB1 receptor model	  (212) 
was used in the structure-based virtual screening of all purchasable ZINC subset of natural 
products for the identification of new natural product chemotypes as CB modulators. For protein-
ligand interaction studies, CB2 model	  based on the bovine rhodopsin template was used (119). 
The protein was prepared using the Protein Preparation Wizard (PPW) (213)	  implemented in the 
Schrödinger suite that involved steps including addition of hydrogen, bond order, assignment of 
atomic charges, and all atoms including hydrogen optimization. The maximum root mean square 
	   68	  
deviation (RMSD) of the atom displacement for terminating the minimization step was set to be 
less than 0.5 Å. One of the key residues, Trp2795.43 (104, 214) located in TM5 was used as a 
centroid for receptor grid generation, and Lys192 (215) located in TM3 was used as an H-bond 
constraint for the virtual screening study. The virtual screening workflow (VSW) of the 
Schrödinger suite was used for in silico screening of the prepared database. 
The standard Ballesteros and Weinstein amino acid numbering system (216) is used for 
referring specific amino acids in the CB1 receptor. In general, the Ballesteros-Weinstein 
numbering (in superscript) used to indicate the relative position of amino acid residues in the 
CB1 receptor sequence including the TM helices. 
3.2.2. Database preparation 
A commercially available ZINC subset of 181,317 natural products downloaded from 
http://www.zinc.docking.org (6/21/2013) was prepared at physiological pH (7.4 ± 2.0) to 
generate all of the possible tautomers and ionized states (160). The prepared database with ~0.3 
million compounds were filtered for drug-likeness using custom a filtration criteria (MW ≤ 700; 
LogP ≤ 5; No of HBA ≤ 10; No. of HBD ≤ 5; No. of RB ≤ 10 and total polar surface area  ≤ 140) 
that afforded a total of 278,037 compounds. 
3.2.3. Structure-based virtual Screening: docking and scoring 
The docking of the filtered set of 278,037 compounds into the generated CB1 receptor 
grid was accomplished in two steps. In the first step, the Glide (162) standard precision (SP) 
method and flexible ligand sampling was used. During docking, a reported key residue 
Lys1923.28 (215)was used as one H-bond constraint. In the second step, top ranked 2000 
compounds were then subjected to the extra precision (XP) (217) docking into the generated 
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CB1 receptor grid to eliminate false positives that may result from SP docking. The XP docking 
method applies a more extensive sampling and advanced scoring algorithm, and hence in 
computationally more intensive. The top ranked compounds from the XP docking were then 
considered for further post-processing, clustering, binding mode analysis and final hit selection. 
3.2.4. Hit post-processing and selection 
A total of 618 compounds resulted from the second step of XP docking were considered 
for further analysis. Considering a Glidescore cutoff of -8.00, a total of 192 compounds were 
identified. These 192 compounds were then clustered using docking score and 2D fingerprint 
properties of ligands using the Canvas (218)	  of the Schrödinger suite (www.schrödinger.com). 
The final assessment of potential CB1 hits was done by visual inspection of the receptor and hit 
interaction geometry. In general, the visual inspection relied on: 1) the formation of H-bond 
interaction between ligand and the Lys1923.28 of the CB1 receptor; 2) favorable orientation of the 
hydrophobic part of the ligand into the receptor active site; 3) Hydrophobic contacts between 
ligand and receptor. Altogether, a set of 32 hits was identified, while 18 were selected for 
purchase and in vitro sampling. 
3.2.5. Procurement and Purity Assessments of Selected Hits 
All 18 compounds were purchased from InterBioScreen Ltd, Russia (219). The vendor 
had verified that each compound had more than 92% purity by NMR and Mass spectroscopy 
(MS). To further validate the purity of purchased compounds, we performed characterization 
using the HPLC, NMR and mass spectroscopic methods. 
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3.3. Biological Methods 
3.3.1. Reagents 
Buffer reagents were purchased from Sigma-Aldrich (St. Louis, MO). All radioligands 
and MicroScint were purchased from PerkinElmer (Waltham, MA). Non-labeled controls were 
purchased from Tocris Bioscience (Minneapolis, MN). Membrane preparation was made using a 
Tris-HCl buffer (50nM Tris-HCl), pH 7.4. Dilutions of membrane, radioligand and control/test 
compounds were made in aTris-EDTA buffer (50mM Tris-HCl, 20mM EDTA, 154mM NaCl 
and 0.2% fatty-acid BSA), pH 7.4. 
3.3.2. Cell Culture 
HEK293 cells (ATCC, Manassas, VA) were stably transfected via electroporation with 
full-length human recombinant cDNA (OriGene, Rockville, MD) for cannabinoid receptor 
subtypes 1 and 2. These cells were maintained at 37°C and 5% CO2 in a Dulbecco’s Modified 
Eagles’ Medium (DMEM) and F-12 HAM nutrient mixture (50/50), supplemented with 2 mM L-
glutamine, 10% fetal bovine serum, 1% penicillin−streptomycin, and G418 antibiotic solutions. 
3.3.3. Membrane Preparation 
Membranes were made by washing the cells with cold PBS. The cells were lysed and 
scraped in cold Tris-HCl, pH 7.4 and then centrifuged at 5,200 x g for 10 min at 4°C. The 
supernatant was discarded and the pellet was resuspended in the same buffer and homogenized 
via Sonic Dismembrator Model 100 (Fisher Scientific, Pittsburgh, PA) for 30 seconds and then 
centrifuged at 1,000 x g for 10 min at 4°C. The supernatant was saved and the pellet underwent 
the suspension and homogenization process 2 more times with the same conditions. The 
supernatants were combined and centrifuged at 23,300 x g for 40 minutes at 4°C. The pellet was 
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re-suspended in cold Tris-HCl buffer, aliquoted into 2 mL vials and stored at -80°C. The total 
protein concentration was determined using a Pierce BCA Protein Assay Kit (Thermo Scientific, 
Rockford, IL) using to manufactures instructions. 
3.3.4. Radioligand Receptor Binding Studies 
For each assay, non-specific binding was determined using 10 µM of CP 55,940 as a 
positive control and total binding was ascertained with 0.1% DMSO in Tris-EDTA buffer. Each 
test well contained 50 µL of radioligand ([3H]-CP 55,940), 50µL of compound, control or 
vehicle and 100-µL cell membrane. The assays were incubated for 90 minutes at 37°C. The 
reaction was terminated via rapid filtration with cold Tris-HCl with 0.1% BSA through a 
UniFilter GF/C 96-well plate pre-soaked with 0.5% PEI. When the filters were dry, 25 µL 
MicroScint-20 was applied to each filter and the plates were read on a TopCount NXT HTS 
Microplate Scintillation Counter (PerkinElmer, Waltham, MA) where the counts per minute 
(CPM) were recorded. 
The Kd of the radioligand for each receptor was established through a membrane 
evaluation and saturation binding experiment. For the membrane evaluation experiment 1-10 µg 
of membrane was incubated with 1 nM of [3H]-CP 55,940. Total, specific, and non-specific 
bindings were used to calculate the % binding of the non-labeled control to receptor. The 
membrane concentration exhibiting good % binding (>90%) and total binding with high signal 
(thousands of CPM) was used as the optimal membrane concentration for the assay. For the 
saturation assay, the optimal membrane concentration and 0-10nM of [3H]-CP 55,940 were 
incubated with 10 µM of a non-labeled CP 55,940 or 0.1% DMSO in buffer. Data was analyzed 
by a non-linear curve fit model using GraphPad Prism 5.04 software (GraphPad, La Jolla, CA) 
and the Kd value was calculated (44, 220). 
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General screening was performed using the optimal concentration of membrane with a 
radioligand concentration ≤ to the Kd. Each compound was test at 10 µM in triplicates. The 
assays were performed as stated above. Non-specific binding was subtracted from total binding 
to find specific binding. Percent displacement was determined using the following equation: 
 
The competitive binding assay was performed using the optimal concentration of membrane with 
a radioligand concentration equal to the Kd and 12 concentrations of each compound, ranging 
from 0.0032-1000 µM. Each compound was tested in triplicate. The assays were performed as 
stated above. The IC50 and Ki values were calculated by non-linear curve fit model using 
GraphPad Prism 5.0 software. 
3.3.5. CB1 GTPγS functional assays 
 The CB1 GTPγS functional assays were performed as previously described (44, 220) with 
some modifications. The assays were performed in 250 mL of 50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 9 mM MgCl2, 0.2 mM EGTA, 1.4 mg/mL essentially fatty acid free BSA, 50 pM GTPγ35S 
([35S]-Guanosine 5`-(γ-thio)triphosphate (Perkin Elmer, Waltham, Massachusetts), and 30 mg 
membrane protein per well harvested from HEK293 cells stably transfected with a plasmid 
overexpressing the human cannabinoid type 1 receptor. Agonist assays were run with 12 
independent 4-fold serial dilutions in triplicate of the test compound and CP 55,940  from 10 
mM to 2.4 pM. Controls consisted of Emax (10 mM of unlabeled CP 55,940), non-specific 
binding (40 mM of non-labeled GTPγS salt), and basal (vehicle only). Plates were incubated 90 
minutes at 37°C with gentle agitation in 96-well microplates, harvested with a Perkin Elmer 
FilterMate Harvester through Unifilter GF/B filter plates (prewetted for 30 m with 0.3% BSA) 
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and then washed 10X ~300 mL with ice-cold 50 mM TrisHCl, pH 7.4. The filterplates were 
dried at 50°C for at least 30 m. The radioactivity retained on the filters was quantified by adding 
50 mL MicroScint20 per well, incubating the filter plate overnight at room temperature to allow 
the radioactivity to solubilize into the scintillation fluid, and counting on a TopCount NXT 
Microplate Scintillation counter (220-222). Percent over basal was calculated in Microsoft Excel 
by subtracting the mean basal control from each value obtained and then dividing by the basal 
specific activity (mean basal control – mean non-specific binding control). Dose response curves 
(± S.E.M.) of percent over basal vs. log of the molar concentration of unlabeled ligand(s) were 
generated by a nonlinear curve fit model using GraphPad Prism 5.0 software. 
3.3.6. CB2 GTPγS functional assays 
 The CB2 GTPγS functional assays were performed as previously described (44, 220) with 
some modifications. The assays were performed in 250 mL of 50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 9 mM MgCl2, 0.2 mM EGTA, 1.4 mg/mL essentially fatty acid free BSA, 50 pM GTPγ35S 
([35S]-Guanosine 5`-(γ-thio)triphosphate (Perkin Elmer, Waltham, Massachusetts), and 30 mg 
membrane protein per well harvested from HEK293 cells stably transfected with a plasmid 
overexpressing the human cannabinoid type 1 receptor. Agonist assays were run with 12 
independent 4-fold serial dilutions in triplicate of the test compound and CP 55,940  from 10 
mM to 2.4 pM. Controls consisted of Emax (10 mM of unlabeled CP 55,940), non-specific 
binding (40 mM of non-labeled GTPγS salt), and basal (vehicle only). Plates were incubated 45 
minutes at 37°C with gentle agitation in 96-well microplates, harvested with a Perkin Elmer 
FilterMate Harvester through Unifilter GF/B filter plates (prewetted for 30 m with 0.3% BSA) 
and then washed 10X ~300 mL with ice-cold 50 mM TrisHCl, pH 7.4. The filterplates were 
dried at 50°C for at least 30 m. The radioactivity retained on the filters was quantified by adding 
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50 mL MicroScint20 per well, incubating the filter plate overnight at room temperature to allow 
the radioactivity to solubilize into the scintillation fluid, and counting on a TopCount NXT 
Microplate Scintillation counter. Percent over basal was calculated in Microsoft Excel by 
subtracting the mean basal control from each value obtained and then dividing by the basal 
specific activity (mean basal control – mean non-specific binding control). Dose response curves 
(± S.E.M.) of percent over basal vs. log of the molar concentration of unlabeled ligand(s) were 
generated by a nonlinear curve fit model using GraphPad Prism 5.0 software. 
3.4. Results and discussion 
3.4.1. Structure-based virtual screening of ZINC natural products subset 
We have recently reported an antagonist-bound CB1 homology model (212) based on the 
bovine rhodopsin template structure. The best CB1 model was identified through an enrichment 
study considering a set of known active and inactive CB1 antagonists. This model was 
understood to represent the inactive state of the CB1 receptor, following various characteristics 
of the inactive GPCR state identified through X-ray crystallographic technique (161). Aiming 
towards the identification of novel natural product chemotypes targeting the CB1 receptor, we 
screened in silico the ZINC subset of 278,037 commercially available, drug-like natural products 
for their potential binding with the CB1 receptor model. Figure 3.1 depicts a schematic virtual 
screening workflow used in the present study. We docked a prepared set of ~0.3 million drug-
like compounds into the antagonist-bound CB1 model using the Glide	   (162)	  application of the 
Schrödinger suite (http://www.schrodinger.com) considering its standard precision (SP) method 
that in return yielded a total of 19,301 compounds ranked based on the SP GlideScore. We 
considered a set of 2000 top-scoring compounds (SP GlideScore cutoff ≤ −9.0) and these 
compounds were subjected to another stage of Glide docking utilizing its more precise and 
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robust extra-precision (XP) method (217). This stage afforded a total of 618 successfully docked 
compounds ranked based on the XP GlideScore. We selected a total of 192 compounds 
considering an XP GlideScore cutoff ≤ −8.0. In order to select structurally diverse chemotypes, 
we clustered them based on docking score and fingerprint properties, and the final selection was 
made through visual inspection of predicted binding modes for polar interaction with a key 
residue Lys1923.28 along with other polar and hydrophobic interactions.  
 
Figure 3.1. A workflow used for protein structure-based virtual screening in this study. 
 
It returned a final list of 32 compounds, from which a set of 18 structurally diverse compounds 
(Figure 3.2) were selected for purchase on the basis of their purchaseability (cost and immediate 
availability), and further in vitro testing against CB receptors. 
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Figure 3.2. Chemical structures of the 18 hits selected for in vitro study. 
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3.4.2. In Vitro screening in the competitive radioligand binding assay 
In the preliminary screening, all of the purchased 18 compounds were subjected to in 
vitro CB1 and CB2 activity assays at a single concentration of 10 µM. The chemical structures 
and the observed percent (%) of displacement against CB receptors along with docking scores 
and other drug-like properties of these 18 compounds are summarized in Table 3.1 and Table 
3.2. As shown in Table 3.1, these compounds are structurally unique relative to known small 
molecule CB modulators, and thus confirm the chemotype novelty of all of the tested 
compounds. 
Out of 18 compounds evaluated in the competitive radioligand-binding assay (Table 3.1), 
four natural and structurally-distinct compounds showed low micromolar inhibition of the CB1 
receptor with binding affinity (Ki) ranging from 1.6 to 12.3 µM (Figure 3.3, Table 3.3). 
Meanwhile, three of these unique compounds also exhibited low micromolar CB2 inhibition with 
binding affinity (Ki) ranging from 1.6 to 16.6 µM (Table 3.3). Broadly, these newly identified 
cannabinoid modulators represent four chemical classes, namely hexahydropyrazinone 
(Compound PCB-2), pyran (Compound PCB-12), isoxazole (Compound PCB-16) and 
benzofuran (Compound PCB-18). The two most promising compounds, PCB-2 (CB1 Ki = 1.6 
µM; CB2 Ki = 0.96 µM) and PCB-12 (CB1 Ki = 2.6 µM; CB2 Ki = 2.9 µM), were observed to 
be non-selective CB modulators with high binding affinity towards both of the CB receptor 
subtypes. However, these compounds represent novel natural product chemotypes for further 
optimization of their CB affinity and selectivity. The binding curves of compounds PCB-2, PCB-
12, PCB-16 and PCB-18 in the cannabinoid radioligand assays for CB1 and CB2 receptors are 
shown in figure 3.4. 
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Figure 3.3. Chemical structures of the four new molecules identified as CB modulators. 
 
Among 18 tested compounds, eight were present in the racemic forms (Figure 3.2, Table 3.1). 
The particular stereoisomer of these eight compounds with predicted good docking scores were 
either unavailable or costly. This may be one of the possible reasons why these compounds 
didn’t show expected binding affinity for CB1. One of the racemic compounds, PCB-3 showed 
>50% displacement against CB2 receptor (~10% displacement against CB1), while another 
racemic compound PCB-12 showed >50% displacement against CB1 and CB2 receptors at 10 
µM (Table 3.1). Compound PCB-3 displayed a good binding affinity for the CB2 receptor with a 
Ki value of 2.6 µM.  
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Table 3.1. The percent (%) displacement against CB1 and CB2 receptors for the 18 compounds 
screened in radioactive competition assays. 
Compound   Sample name ZINC code 
Docking 
score CB1 
receptor 
% Displacement at 
10 µM 
CB1  CB2 
   PCB-1* STOCK1N-06857  ZINC00940539 -10.153 14.1 ± 0.6 - 
PCB-2 STOCK1N-34850 ZINC09033729 -9.975 81.8 ± 7.7 67.2 ± 6.8 
 PCB-3* STOCK1N-43108 ZINC09374751 -9.74 9.2 ± 3.7 51.0 ± 5.5 
PCB-4* STOCK1N-43876 ZINC00861983 -9.6 13.9 ± 4.2 - 
PCB-5 STOCK1N-51636 ZINC02118939 -11.119 14.0 ± 3.7 15.5 ± 5.7 
PCB-6 STOCK1N-53876 ZINC02123699 -11.517 28 ± 5.6 26.7 ± 6.0 
PCB-7* STOCK1N-62719 ZINC20755817 -12.295 49.7 ± 2.4 15.7 ± 2.2 
PCB-8* STOCK1N-68672 ZINC08879802 -9.777 30.5 ± 5.8 7.0 ± 2.2 
PCB-9 STOCK1N-69353 ZINC12896219 -9.804 28.6 ± 4.1 30.2 ± 2.4 
PCB-10 STOCK1N-73177 ZINC20763677 -9.014 30.2 ± 4.2 17.3 ± 3.1 
PCB-11* STOCK1N-75513 ZINC40313209 -10.73 37.6 13.1 
PCB-12* STOCK1N-79387 ZINC85875400 -11.723 69.9 63 
PCB-13 STOCK1N-79693 ZINC85877048 -9.638 23.1 ± 5.4 37.4 ± 1.7 
PCB-14* STOCK1N-80140 ZINC85879663 -9.967 18.7 30 
PCB-15 STOCK5S-41625 ZINC02229040 -10.459 57.6 ± 2.1 35.5 ± 4.5 
PCB-16 STOCK6S-13543 ZINC06757795 -9.378 61.8 ± 5.9 40.2 ± 5.5 
PCB-17 STOCK6S-34022 ZINC08823658 -9.818 50.4 ± 3.5 35 ± 8.1 
PCB-18 STOCK6S-39252 ZINC28182437 -10.436 69.0 ± 6.4 61.2 ± 7.1 
Note: *Indicates racemic mixtures. 
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Table 3.2. Physicochemical and other selected properties related to drug-likeness for the all 18 
tested hits. 
Compound MW QPLogP #HBA #HBD PSA(Å2) #RB 
PCB-1* 415.45 1.71 7 3 117.402 8 
PCB-2 442.52 3.886 6 1 87.903 4 
PCB-3* 435.519 4.406 7.200 0.000 91.620 7 
PCB-4* 370.404 3.233 7.450 2.000 98.812 6 
PCB-5 455.525 4.160 7.500 1.250 123.966 9 
PCB-6 441.498 3.403 7.500 2.250 137.364 9 
PCB-7* 448.539 4.696 4.250 3.000 103.898 5 
PCB-8* 455.507 2.872 9.000 1.000 126.134 4 
PCB-9 436.463 2.170 8.500 1.000 132.713 8 
PCB-10 405.45 4.572 4.5 2.25 107.384 8 
PCB-11* 408.410 3.121 5.750 2.000 129.267 4 
PCB-12* 440.47 3.924 7.25 1 109.649 8 
PCB-13 445.474 3.789 4.750 4.000 123.602 5 
PCB-14* 412.456 3.350 6.500 2.000 113.379 9 
PCB-15 478.344 4.918 4.500 3.000 83.400 8 
PCB-16 346.18 3.153 3 2 69.421 2 
PCB-17 437.535 3.971 7.250 1.000 94.545 10 
PCB-18 424.5 4.597 5.25 1 65.049 7 
    CP 55,940 376.573 6.1 3 3 60.70 10 
   Rimonabant 463.79 6.5 1 3 50.16 4 
 
    Note. #HBA, number of HBA; #HBD, number of HBD; #RB, number of rotatable bonds, 
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Table 3.3. The binding affinities (Ki and IC50) of selected compounds against CB1 and CB2 
receptors. 
Compound 
IC50 ± S.E.M. (µM) 
(% Displacement at 10 µM) 
Ki ± S.E.M. (µM) 
 
CB1 CB2 CB1 CB2 
PCB-2# 3.2 ± 1.0 1.92 ± 0.5 1.6 ± 0.5 0.960 ± 0.3 
PCB-7** (49.7%) (15.7%) - - 
PCB-12**# >5.3 ± 1.4 >5.9 ± 0.8 >2.6 ± 0.7 >2.9 ± 0.4 
PCB-15 (57.6%) (35.5%) - - 
PCB-16# 20.8 ± 4.9 (40.2%) 10.4 ± 2.5 NA 
PCB-17 (50.4%) (35.0%) - - 
PCB-18$ 24.6 ± 2.6 33.1 ± 3.5 12.3 ± 1.3 16.6 ± 1.8 
CP 55,940 9.84 nM 8.62 nM 4.9 nM 4.31 nM 
Note: #indicates that value represents compounds affinity of compound up to its solubility limit. 
$Indicates that the chromophore nature of the compound may have interfered with the 
radioligand detection providing a false positive, NA indicates not applicable 
**Indicates racemic compounds 
 
Table 3.4. The functional activity (IC50 and EC50) of selected compounds using GTPγS 
functional assays against CB1 and CB2 receptors. 
 
Compound 
Functional Activity  
IC50/EC50 ± S.E.M. (µM) 
CB1 CB2 
PCB-2# 0.7586 ± 0.2780 Results pending 
PCB-12**# 1.5960 ± 0.7440 Results pending 
PCB-16# 0.1280 ± 0.0448 Results pending 
CP 55,940 0.001022 ± 0.000242 Results pending 
Rimonabant 0.001159 ± 0.0002351 Results pending 
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Figure 3.4. The binding curves obtained for compounds PCB-2, PCB-12, PCB-16, and PCB-18 
in the cannabinoid radioligand-binding assay. The CP 55,940 was used as a positive control. 
 
Further binding analysis revealed that three compounds PCB-7, PCB-15 and PCB-17 exhibiting 
≥50% displacement against CB1 receptor at 10 µM, plateaued well before reaching 100% 
receptor occupancy, indicating no true affinity for the CB1 receptor (Figure 3.5). When full 
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curves could not be obtained due to low affinity or solubility limit of the compounds, the values 
are reported as greater than the last tested concentration (Table 3). 
CB1 Receptor Binding
Log Concentration (M)
[3
H
]-
C
P-
55
,9
40
 S
pe
cf
ic
 B
in
di
ng
(%
 o
f C
on
tr
ol
)
-10 -8 -6 -4 -2
-50
0
50
100
150
Compound 17
CP-55,940
Compound 7
Compound 15
 
Figure 3.5. The binding curves for compounds PCB-7, PCB-15 and PCB-17 obtained from the 
radioligand competitive binding assay. CP 55,940 was used as a positive control. 
 
Compound PCB-18 has a conjugated π-bond system and may be considered as a chromophore. 
At higher concentrations, the chromophore interferes with the radioligand detection system. 
Therefore, it was difficult to precisely determine if the lower radioligand detection was because 
the radioligand was bound to the receptor or if the chromophore was interfering with the 
radioligand detection system. Thus, the IC50 and Ki for such compounds possessing 
chromophore systems could not be accurately determined using our current assay system. 
3.4.3. In Vitro GTPγS functional assays for CB1 and CB2 receptors 
The GTPγS binding functional assay procedure is very similar to binding assay methods 
and is mainly used to analyze the functional effects of agonists, antagonists and inverse agonists 
at GPCRs. The general principle of GTPγS binding assays is shown in Figure 3.6. All 
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compounds mentioned in this study were determined to act as inverse agonists using the GTPγS 
functional bioassay against CB1 receptor (Figure 3.7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Principle of [35S]GTPγS binding functional assay 
 
3.4.4. Protein-ligand interaction	  	  
Compound PCB-2 (Figures 3.8A and 3.8B) exhibited a favorable binding mode with the 
CB1 receptor model including a key H-bond interaction with Lys1923.28 and a π-π stacking 
interaction with Trp2795.43. The methoxy-indole moiety also exhibited a π-π stacking interaction 
with another aromatic residue, Trp2755.39. The orientation of the indole ring inside the 
hydrophobic region of the CB1 receptor provided an added stabilization to the ligand through 
strong hydrophobic interactions 
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Figure 3.7. GTPγS functional curves of (A) compound PCB-2 (B) compound PCB-12 and, (C) 
compound PCB-16 for CB1 receptor. 
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In contrast, docking analysis of this compound with the CB2 model suggested it to exhibit π-π 
stacking interactions with an important residue, Trp1945.43, located on the extracellular side. 
Meanwhile, this compound also exhibited strong hydrophobic interactions with Trp2586.48, 
Phe1173.36, Val2616.51, and Leu2626.52 residues. Distance measurement revealed that the two 
polar residues, Arg177 and Thr1143.33, were within a distance of 3Å of the methoxy and keto 
moiety of compound PCB-2, thus suggesting any possible H-bond formation in case of flexible 
protein (Figures 3.8C and 3.8D). 
The binding mode of compound PCB-12 within the CB1 model demonstrated an H-bond 
interaction with key residue Lys1923.28 of the CB1 model. The Trp2795.43 residue of CB1 
exhibited dual interactions with this compound (Figures 3.9A and 3.9B). The benzodioxazole 
oxygen of 12 participated in an H-bond formation with NH of Trp2795.43, while the benzene ring 
showed π-π stacking interaction with Trp2795.43. Overall, this compound exhibited strong 
interactions with the CB1 receptor and thereby, displayed CB1 inhibitory activity in the 
micromolar range (Ki = 2.6 µM). 
Meanwhile, it also exhibited quantitatively similar binding affinity for the CB2 receptor 
(Ki = 2.9 µM). Docking analysis of the S enantiomer of this compound with the CB2 model 
exhibited 1,3-benzodioxazole moiety having π-π stacking and H-bond interactions with 
Trp1945.43 residue (Figures 3.9C and 3.9D). In addition, thiophenyl moiety exhibited π-π 
stacking interaction with Phe281. Meanwhile, the 1,3-benzodioxazole and thiophenyl 
substructures are stabilized through strong hydrophobic interactions with several hydrophobic 
residues, namely Met2656.55, Pro176, Leu1915.40 and Trp2586.48, Phe1173.36, Val2616.51, 
Leu2626.52, and Ile2987.52. 
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Figure 3.8. The putative binding modes for the most active compound PCB-2 into the CB1 (A 
and B) and CB2 (C and D) receptor models. The two-dimensional interaction views are shown 
on the left-side, while three-dimensional interaction views are shown on the right-side. Ligand 
(cyan colored carbons) and protein binding site (dark grey colored carbons) residues are shown 
as sticks. 
 
Compound PCB-16 is relatively smaller in size compared to the other three compounds (Figure 
3.3). This compound fit well within the CB1 binding site and formed favorable binding 
interactions that include H-bond interactions with Lys1923.28 and Asp3666.58, and π-π stacking 
interactions of oxazole and bromobenzene moieties with Trp3566.48 and Trp2795.43, respectively 
(Figure 3.10 A and B). One of the possible reasons for the lower CB1 affinity of this compound, 
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compared to PCB-2 and PCB-12, is the lack of an additional hydrophobic group that could fit 
into a hydrophobic pocket of the CB1 receptor leading to increased binding and stability. 
Compound PCB-18 (Figure 3.10 C and D) showed stronger interaction with the CB1 model and 
thus could show better affinity toward CB1 in comparison to compound PCB-16 (Figure 3.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. The putative binding modes for the most active compound PCB-12 into the CB1 (A 
and B) and CB2 (C and D) receptor models. The two-dimensional interaction views are shown 
on the left-side, while three-dimensional interaction views are shown on the right-side. Ligand 
(cyan colored carbons) and protein binding site (dark grey colored carbons) residues are shown 
as sticks. 
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Figure 3.10. Putative binding modes of compound PCB-16 (A and B) and PCB-18 (C and D) 
with the CB1 model. Ligands are shown as sticks with carbon colored into cyan color. Protein 
amino acids are shown as sticks with carbon colored into grey color. 
 
Unfortunately, the experimental activity of compound PCB-18 could not be determined 
accurately by our current CB1 detection system because of the presence of a chromophore group 
(conjugated double bond) in the ligand. Docking analysis revealed that compound PCB-18 
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exhibited multiple H-bond interactions with Lys1923.28 and Asp3666.58, and an aromatic π-π 
stacking interaction with key residues, Trp2795.43 and Trp3797.35, of the CB1 model. 
3.4.5. Molecular dynamics studies 
In order to understand the stability and interaction patterns of compound PCB-2 with 
CB1 and CB2 receptor, we performed 50 ns MD simulations with the NAMD suite using the 
CHARMM general force field. Each of the docked complexes of the best compound PCB-2 with 
CB1 and CB2 receptor models were separately embedded into the pre-equilibrated POPC (1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) lipid bilayer solvated with water and system 
was neutralized using KCl and set an ionic strength of 0.15 M. The total number of atoms for 
CB1 was 66,177 including 36 K+ and 48 Cl¯ ions, about 13,399 water molecules, and 154 (75 top 
and 79 bottom) POPC molecules in CB1 receptor while for CB2, the total number of atoms was 
61,810 including 34 K+ and 46 Cl¯ ions, about 12,886 water molecules, and 137 (66 top and 71 
bottom) POPC molecules. Equilibration of the system was performed at constant pressure and 
temperature (NPT ensemble; 303 K, 1 bar). The system was subjected to an initial minimization 
for 25,000 steps (25 ps) keeping the protein backbone fixed, which was followed by 20,000 steps 
(20 ps) of minimization without fixing anything (to allow system to relax freely). Thereafter, the 
system was equilibrated in six consecutive steps. An NPT simulation was run on the equilibrated 
structure for 5000 ps keeping the temp at 303 K and pressure at 1 bar using Langevin piston 
coupling algorithm. The integration time step of 1.0 fs was set for simulations, the SHAKE 
algorithm was used to constrain lengths of all chemical bonds involving hydrogen atoms at their 
equilibrium values and the SETTLE algorithm was used to restrain water geometry rigid. Non-
bonded van der Waals interactions were treated by using a switching function at 10 Å and 
reaching zero at a distance of 12 Å. The particle-mesh Ewald algorithm was used to handle long-
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range electrostatic forces. The graphs of RMSD vs. time have plotted between protein backbone 
and ligand heavy-atoms against both CB proteins and compound PCB-2, shown in Figure 3.11. 	  
While observing the complexes of CB1 and CB2 with ligand PCB-2, it was observed that 
protein RMSD (Figure 3.11) has attained a significant stable conformation after 30 ns and 33 ns 
for CB1 and CB2 receptor, respectively from its original poses. In a similar fashion, the RMSD 
for the ligand PCB-2 with the CB1 receptor, initially rose to 3.2 Å and kept deviating at an 
average RMSD of ~1-1.5 Å to 50 ns; however, the RMSD for the ligand PCB-2 with the CB2 
receptor elevated significantly at the start to 36 ns and became stable to the final 50 ns. This 
correlated stability of the ligand PCB-2 and the CB2 receptor suggested a better binding when 
compared to the binding of the CB1 receptor by the ligand PCB2. 
MD simulation studies on compound PCB-2 revealed that the indole-3-methyl 
substructure is highly dynamic in both of the CB protein models. CB1 protein residues Arg186, 
Lys192, Tyr275, Asp366, Trp379, and Ser383 are involved in the H-bond interactions with 
compound PCB-2, while CB2 protein residues Tyr190, Trp194, Ile198, Trp258, and Ser268 
showed side chain H-bond interactions and Val113 and Val261 showed backbone H-bonds 
(Figure 3.12). The key residue Lys192 did not make longer H-bonding with indole group; 
however, it was close to this group (~5-7 Å) during the whole 50 ns dynamics. It may have a 
cation-π interaction with the indole ring of the PCB-2 molecules. To understand the proper 
interaction pattern of Lys192 with PCB-2 molecules, future longer dynamics may be needed. 
The RMSD plots have been generated using the GRACE plotting tool. 
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Figure 3.11. Plot of (A) protein CB1 backbone and ligand PCB-2 RMSDs vs. time, (B) protein 
CB2 backbone and ligand PCB-2 RMSDs. 
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Figure 3.12. 3D ligand-protein interactions of compound PCB-2 with CB1 (A) and CB2 (B) 
models (results from MD simulation). 
 
B 
A 
	   95	  
3.4.6. Analogs exploration: Analogs of the virtual screening hits PCB-2, PCB-12 and PCB-16 
were further explored because these structures were novel and showed promising nanomolar to 
micromolar range functional activity towards CB1 and CB2 receptors (Table 3.3 and Table 3.4). 
The main goal of the exploration of these hits is to get more active and selective compounds for 
either of the CB receptors. The compounds contain similar scaffolds as PCB-2, PCB-12 and 
PCB-16 were selected from the Zinc database subset of natural products having >80 similarity. 
The selected 19 compounds were purchased from Molport. The purchased compounds were 
further characterized by NMR, MS and HPLC.  
In the preliminary screening, all of the purchased nineteen compounds (Figures 3.13) 
were subjected to in vitro CB1 and CB2 activity assays at a single concentration of 10 µM. The 
compounds which showed >50% displacement against CB receptors were further tested for Ki 
and IC50 values using the competitive radioligand-binding assay (Table 3.5 and Figure 3.14). In 
addition, some of the selected compounds which showed better binding affinity towards CB1 and 
CB2 receptors (PCB-210, PCB-211, PCB-163, PCB-164) were further tested for GTPγS 
functional assays against CB1 and CB2 receptor (Table 3.6). 
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Figure 3.13. Structures of compound PCB-2, PCB-12 and PCB-16 analogs tested for the CB1 
and CB2 activity. 
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Table 3.5. The percent (%) displacement and the binding affinity (Ki) of PCB-2, PCB-12, and 
PCB-16 analogs against CB1 and CB2 receptors in radioactive competition assays. 
Compound MW 
(% Displacement at  
10 µM) 
Ki ± S.E.M. (µM) 
CB1 CB2 CB1 CB2 
21 390.4 6.9 33.5 ND >10.0 
22 421.5 22.4 70.3 ND > 0.6044 ± 0.2682 
23 403.5 42.4 68.5 >10.0 † 0.4774 ± 0.2189 
24 389.4 51.2 55.8 † 1.266 ± 0.453    † 2.630 ± 0.504 
25 419.5 28.1 48.6 >10.0 >10.0 
26 417.5 61.7 80.3 3.908±0.804 1.134 ± 0.126 
27 426.5 23.3 20.7 >10.0 >10.0 
28 433.5 69.0 68.1 0.9269 ± 0.2972 32.491 ± 1.119 
29 369.5 60.4 61.3 †0.2255±0.2215 † 0.9327 ± 0.2533 
210 381.5 71.7 45.3 0.4092 ± 0.2661 >10.0 
211 383.5 70.6 66.6 †0.5721±0.1642 † 1.914 ± 0.972 
212 399.5	   49.6 31.6 >10.0            >10.0 
213 299.3	   13.4 23.2 ND >10.0 
121 442.5 37.9 51.0 >10.0 †4.035 ± 2.078 
161 436.3 37.4 44.6 >10.0 >10.0 
162 436.3 3.9 28.4 ND >10.0 
163 454.3 72.0 81.1 	  	  0.4870 ± 0.1516  1.084 ± 0.141 
164 444.4 29.8 97.2 Not converged  0.1556 ± 0.0173 
165 321.3 33.0 - >10.0 - 
CP 55,940 376.6   0.002162±0.000420  0.001185±0.000128  
* Compounds were tested up to their solubility limit; concentrations at 100 µM and above 
precipitated in aqueous assay buffer. †	  =	  >	  Compound curves did not reach baseline; therefore Ki 
values are reported as “greater than” to indicate this fact. ND = Not determined. 
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Figure 3.14. The binding curves obtained for compounds (A) 22 (CB1) and 23 (CB1), (B) 24 
(CB1 and CB2), (C) 26 (CB1 and CB2), (D) 28 (CB1 and CB2), and (E) 29 (CB1 and CB2), (F) 
211 (CB1 and CB2), (G) 210 (CB1) and 121 (CB2), (H) 163 (CB1 and CB2), (I) 164 (CB2), in 
the cannabinoid radioligand-binding assay. CP 55,940 was used as a positive control.  
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Table 3.6. The functional activity (IC50 and EC50) of compounds PCB-2, PCB-12, PCB-16 and 
their analogs using GTPγS functional assays against CB1 and CB2 receptors. 
 
Compound PCB-2, a virtual screening hit, showed promising micromolar activity for 
CB1 and CB2 receptors. To explore the structure activity of compound 2, we purchased >80% 
similar compounds to PCB-2, which varies at only the N-2 position. The PCB-213 did not show 
any CB1 or CB2 activity, which confirmed the role of substitution at the N-2 position of 
compound PCB-2. The PCB-23 and PCB-24, where the N2 position of compound PCB-2 is 
substituted by 4-F-phenylethyl and phenylethyl groups, respectively, showed promising activity 
towards the CB2 receptor (See Table 3.5); however, substitution of 2-hydroxyphenylethyl (PCB-
25) decreases the affinity towards CB1 and CB2 receptors. 
PCB-21, a 3-pyridine methyl substitution at the N2-position of compound PCB-2, which 
lacks one extra carbon chain compared to PCB-22, PCB-23, PCB-25 and PCB-28, displayed no 
affinity towards CB1 or CB2 receptors; however, the 4-methoxyphenylmethyl moiety (PCB-24) 
Compound 
Functional Activity  
IC50/EC50 ± S.E.M. (µM) 
CB1 CB2 
PCB-2# 0.7586 ± 0.2780 Results pending  
210             0.1178 ± 0.0401 - 
211            0.0005827 ± 0.0004337 Results pending 
    PCB-12**# 1.5960 ± 0.7440 Results pending 
PCB-16# 0.1280 ± 0.0448 - 
163 2.0230 ± 1.647  
164 Not converged Results pending  
CP 55,940 0.001022 ± 0.000242 Results pending 
Rimonabant 0.001159 ± 0.000351 Results pending 
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displayed slightly higher affinity towards CB1 compared to CB2. When an additional carbon is 
added to PCB-24 (see PCB-28), the binding affinity towards CB1 (Ki= 0.9269 ± 0.2972 µM) is 
much better than CB2 (Ki= 32.491 ± 1.119 µM). 
In addition, when the N-2 position is substituted by n-pentyl and n-hexyl moiety, representing 
compounds as PCB-29 and PCB-211, respectively, showed higher affinity towards CB1 than 
CB2 compared to compound PCB-2. The functional activity of PCB-211 was found to be 0.5827 
± 0.4337 nM with inverse agonist effects (Figure 3.15 B). When the 3-phenylpropyl (PCB-26) 
group was substituted at the N2 position, it showed good activity for either of the receptors; 
however, the 3-morphinopropyl (PCB-27) group substitution at the N2 position diminished CB 
activity. Particularly, the cyclohexyl substitution at the N-2 position (PCB-210) led to a selective 
and potent CB1 hit (0.4092 ± 0.2661 µM). This compound was also tested for full functional 
curve for CB1 GTPγS functional assay and showed potent nanomolar CB1 inverse effect with a 
good IC50 of 117.8 ± 40.1 nM (Figure 3.15 A). The analog PCB-212, which consists of an 
isopropoxylpropyl group at the N2-position, was found to be CB receptors inactive. Overall, we 
can interpretate that n-alkyl substitution or hydrophobic substitution (cyclic) is necessary for 
CB1 activity and selectivity. Any polar substitution at the end of the alkyl chain leads to loss of 
CB activity. For CB2 activity, a two or three carbon chain with phenyl or p-fluoro phenyl is 
necessary to exhibit CB2 activity and selectivity. 
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Figure 3.15. GTPγS functional curves of (A) compound PCB-210 and (B) compound PCB-211 
for CB1 receptor. 
  
In a similar fashion, we explored the SAR of compound 16 (CB1= 10.4 ± 2.5 µM) and 
(CB2 > 10 µM) to get more potent and CB selective compounds. The functional CB1 GTPγS 
assays revealed that compound 16 is a CB1 inverse agonist with a potent IC50 activity. The shape 
similarity score of compound 16 with well-known inverse agonist rimonabant is calculated to be 
0.75 (Figure 3.16).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. Overlay representation of compound PCB-16 (carbon in yellow), and PCB-163 
(carbon in green) with rimonabant (carbon in turquoise). 
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We explored the 1,5-dihydroxybenzene position of compound PCB-16. We purchased 5 
compounds which differed at the 5-hydroxyl group of 1,5-dihydroxybenzene position of 
compound PCB-16, [PCB-(161-165)]. The benzyl (PCB-161) and p-bromo benzyl (PCB-162) 
substitutions at the 5-hydroxyl group of 1,5-dihydroxybenzene position of compound PCB-16 
possessed >10 µM CB activity, which can be considered as inactive. The p-fluorobenzyl 
substituted analog PCB-163, led to a potent and CB1 selective compound. The compound PCB-
163 was tested for CB1 GTPγS functional assays, and it was found to be a CB1 inverse agonist 
with an EC50 of 2023.0 ± 1647 nM (Figure 3.17). Interestingly, the n-hexyl substitution at the 4-
position and the methoxyl at the 5-position resulted in PCB-164, which had high affinity and was 
a CB2 selective compound (Ki=0.1556 ± 0.0173 µM). These experimental results confirmed that 
for CB activity, the 4-bromophenyl moiety is necessary along with p-fluorobenzyl (PCB-163) 
and n-hexyl substitution at the 4-position and the methoxy at the 5-position (PCB-164). 
 
 
 
 
 
 
 
Figure 3.17. GTPγS functional curve of compound PCB-163 for CB1 receptor. 
 
In addition, we also tried to explore the SAR of compound PCB-12, but other structurally 
related analogs were available as racemates, and hence, we did not purchase more analogs. We 
only purchased one analog of compound 12 (PCB-121) with known stereochemistry. This 
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compound showed micromolar activity (Ki = ~5 µM) for CB2. Analog PCB-121 did not show 
affinity towards CB1.  
Overall, our structural exploration of identified hits such as PCB-2, PCB-12 and PCB-16 resulted 
in nanomolar range compounds, some of which have higher preference for CB1 (PCB-28, PCB-
210, PCB-211 and PCB-163) and others for CB2 (PCB-22, PCB-23, and PCB-164).  
Our future strategy is to get selective and higher affinity CB1 inverse agonists devoid of 
CNS-related side effects, which is the major drawback of CB1 antagonists/inverse agonists. In 
other words, we need to block the CB1 receptor in peripheral tissues in such a way that 
compounds do not cross the blood-brain barrier (BBB). This strategy can be achieved in the 
future by 1) using charged molecules, since charged compounds do not normally cross the BBB 
unless transported by specific transporters and, 2) adding functional groups which have relatively 
high topological polar surface area (TPSA) such as sulfonamide and sulfamide to the 
compounds, since higher TPSA corresponds to lower penetration into the CNS. 
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Table 3.7. Physicochemical and other selected properties related to drug-likeness for the all 19 
tested hits. 
Compound MW QPLogP #HBA #HBD PSA (Å2) #RB 
PCB-2# 442.52 3.886 6 1 87.903 4 
21 390.4 1.965 7 0 85.672 3 
22 421.5 3.701 6 0 74.009 4 
23 403.5 3.461 6 0 74.011 4 
24        389.4 2.942 7 0 72.379 3 
25 419.5 2.627 7 1 93.257 5 
26 417.5 3.831 6 0 74.076 5 
27 426.5 1.206 9 0 88.808 5 
28         433.5 3.522 6 0 82.296 5 
29 369.5 2.834 6 0 73.524 5 
210 381.5 2.802 6 0 71.000 1 
211 383.5 3.230 6 0 73.524 6 
212 399.5 2.584 7 1 81.366 6 
213 299.3 0.946 5 1 87.758 1 
PCB-12 440.5 3.908 7 1 106.023 8 
121 442.5 3.849 7 2 116.415 10 
PCB-16 346.2 3.163 3 2 69.058 2 
161 436.3 5.916 3 1 53.471 4 
162 436.3 5.919 3 1 53.465 4 
          163        454.3 6.154 3 1 53.472 4 
          164 444.4 5.829 3 1 53.606 7 
          165 321.3 3.228 3 2 68.574 2 
CP-55, 940 376.6 6.1 3 3 60.70 10 
Rimonabant 463.8 6.5 1 3 50.16 4 
Note. #HBA, number of HBA; #HBD, number of HBD; #RB, number of rotatable bonds. 
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3.5. Conclusion 
Through the in silico screening of the ZINC subset of natural product database against a 
CB1 receptor model, we have identified 4 small molecules as potential cannabinoid modulators. 
Although these compounds exhibited rather low micromolar inhibition of the CB1 and CB2 
receptor, they represent novel natural product chemotypes for further optimization of their 
affinity and selectivity toward the particular CB receptor. Notably, the most promising 
compounds PCB-2, PCB-12 and PCB-16 were tested for their characteristics (agonist/antagonist) 
in the GTPγS cannabinoid functional assay and found to be CB1 receptor inverse agonists. The 
inverse agonists nature of these compounds on CB1 receptors validated our CB models because 
these molecules were identified through the SBVS of the inactive-state of CB1 model. In terms 
of the protein-ligand interaction, the identified hits exhibited strong interaction with both of the 
CB receptor subtypes, and explained well the observed binding affinity. Further, our structural 
exploration of identified hits PCB-2, PCB-12 and PCB-16 resulted in nanomolar range 
compounds which showed preference for CB1 (PCB-28, PCB-210, PCB-211 and PCB-163) and 
CB2 (PCB-22, PCB-23, and PCB-164). The functional activities of PCB-210, PCB-211 and 
PCB-163 showed them to be inverse agonists of the CB1 receptor. The analog of compound 2 
(PCB-211) showed very promising inverse agonist activity in the subnanomolar range. Docking 
studies showed that compounds PCB-16 and PCB-211 form similar interactions with CB1 as 
were found for rimonabant (SR141716A), but PCB-211 had a slightly different binding pose to 
CB1. These scaffolds are structurally distinct from those of known CB1 inverse agonists; 
therefore, further research is needed involving development of novel CB1 inverse agonists 
through modification/optimization of molecular properties such as the polar surface area and 
hydrophilicity, in order to be able to avoid the central activity observed with SR141716A. 
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4.1. Introduction 
Several GPCRs have been shown to contain allosteric binding sites for 
endogenous/synthetic ligands which are discrete from the agonist-binding (orthosteric) site (125, 
223). The binding of allosteric modulators leads to a conformational change of the receptor, 
which affects the affinity and/or efficacy of the orthosteric (endogenous) ligands, thereby fine-
tuning its actions. The CB2 receptor may be a useful target for treating human diseases such as 
pain, inflammation, amyotrophic lateral sclerosis (ALS), cancer, ischemic/reperfusion injury, and 
osteoporosis (97); however, prolonged activation of the CB2 receptor may cause 
immunosuppression and bone loss (89, 134, 135). Allosteric modulators (AMs) exhibit distinct 
therapeutic advantages over orthosteric ligands in terms of enhanced target specificity and 
reduced off-target side effects (125). The CB2 selective allosteric modulators include both 
positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs). To date, only 
a few AMs of the CB2 receptor have been identified with micromolar activity, and there is 
insufficient knowledge of allosteric site(s) within the CB2 receptor for efficiently targeted 
searches for new potent AMs.  Therefore, we aim to identify and characterize allosteric site(s) of 
known CB2 AMs (136), dihydro-gambogic acid (DHGA) and trans-β-caryophyllene (TBC), and 
their potential modes of interaction with the CB2 receptor. The multi-template based active state 
model of the human CB2 receptor (Figure 4.1) was used for the allosteric site characterization of 
CB2 allosteric modulators.  
 
 
 
 
	   111	  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. CB2 receptor model from the extracellular side depicting some key residues of CB2 
and a disulfide bridge in the second extracellular loop (e2). 
4.1.1. Trans-β-caryophyllene (TBC) 
Trans-β-caryophyllene (TBC) (Figure 1.13) is a natural bicyclic sesquiterpene plant 
volatile found in the essential oils of various plants including rosemary (Rosmarinus officinalis), 
cinnamon (Cinnamomum zeylanicum), hops (Humulus lupulus), clove (Syzygium aromaticum), 
black pepper (Piper nigrum), basil (Ocimum gratissimum and Ocimum micranthum), and 
cannabis (Cannabis sativa). β-caryophyllene contributes to the unique aroma associated with 
plant oils similar to most terpenes. It is usually found in a mixture with its isomer 
isocaryophyllene and α-humulene (a ring opened isomer) or its oxidation product Trans β-
caryophyllene oxide (TBO). TBC, a dietary compound, has been reported as a cannabinoid due 
to its CB2 agonist effect. This compound has shown anti-inflammatory effects via the CB2 
receptor in mice. TBC constitutes 3.8–37.5% of the essential oil of cannabis sativa. It has been 
reported that TBC, which is isolated from the cannabis sativa, is a selective CB2 agonist with a 
Ki of 780 ± 12 nM activity. Due to its cannabinoid property (CB2 selective agonist), it has a 
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potential for treating therapeutic beneficial such as arthritis, pain and metabolic disorder. 
Recently, Maheshwari et al (136) reported TBC as a highly selective dietary CB2 cannabinoid 
with unique ago-allosteric properties by applying in vitro and in vivo experiments. From their 
studies, they suggested that TBC might function as a negative ago-allosteric modulator with	  a	  Ki	  (binding	  affinity)	  of	  2.37	  μM	  in a probe dependent manner.                            	  
4.1.2. Gambogic acid (GA)  
Gambogic acid is a xanthonoid which is derived from the resin isolated from the Garcinia 
hanburyi tree. It exhibits pro-apoptotic and anti-inflammatory properties. Dihydro-gambogic 
(DHGA), (Figure 1.14) a derivative of gambogic acid has shown negative AM effects on the 
CB2 receptor in a probe-dependent manner and was reported by Maheshwari et al 2011 (136). 
4.2. Computational Method 
4.2.1. Homology modeling of CB2 receptor in active state 
With notable advancements made in X-ray crystallization techniques as well as structural 
biology, there has been impressive progress in X-ray structure determination of GPCRs. Today, 
there are a total of eleven GPCRs for which medium to high-resolution crystal structures have 
been solved with small molecule ligands or modulators. These eleven GPCRs are rhodopsin, the 
β1 and β2 adrenergic receptors, adenosine A2A receptor, chemokine CXCR4 receptor, dopamine 
D3 receptor, histamine H1 receptor, sphingosine-1-phosphate receptor, and the kappa (κ)-, mu 
(µ)- and delta (δ)-opioid receptors (224). These X-ray structures bound to different classes of 
modulators like agonists, inverse-agonists, and antagonists, have delineated some common 
mechanisms of GPCR activation and inactivation. 
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In the area of GPCR drug discovery toward selective activation (agonism) of GPCRs of 
pharmaceutical interests for drug discovery, the X-ray structure determination of the β2-
adrenergic receptor-Gs complex in the active state represents the most significant breakthrough. 
In addition, there are other X-ray structures of Class-A GPCRs bound to agonists available in 
their active states, although some of these structures include fusion proteins (T4-lysozyme or 
nanobody), either in N-terminus or third intracellular loop (C-terminus), primarily for 
enhancement in their stabilization. Meanwhile, continuous improvement has been made in 
protein structure prediction methods for providing good-to-high quality models considering the 
above X-ray structures. These advances have opened new perspectives for structure-based drug 
discovery. Herein, we prepared an active state CB2 receptor homology model (K. K. Roy et al., 
unpublished) by utilizing known active state GPCR 3D structures as templates.  
4.2.1.1. Template selection and sequence alignment 
None of the available GPCR structures share ≥ 30% sequence identity with the hCB2, 
and therefore, the use of multiple templates for homology modeling is recommended. Promising 
active state templates for CB2 receptor modeling are (i) the β2AR-Gs complex (PDB-ID: 3SN6) 
(225)  (ii) nanobody stabilized β2AR-agonist complex (PDB-ID: 3P0G) (226), (iii) β1AR-agonist 
complex (PDB-ID: 2Y02) (227), (iv) the meta-rhodopsin II (PDB-ID: 3PQR) (228), and (v) an 
agonist-bound Adenosine A2A receptor (PDB-ID: 2YDV) (229). Figure 4.2 shows multiple 
sequence alignments of the CB2 receptor using β1AR, β2AR, Adenosine A2A and the meta-
rhodopsin II as templates. 
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Figure 4.2. Multiple sequence alignment. Identical residues are colored red while similar 
residues are colored blue. TM domains are enclosed in boxes. 
4.2.1.2. Homology modeling, refinement and induced-fit docking 
Homology models of the hCB2 receptor were developed using the MODELLER (v9.12) 
program (230). A reported disulfide bridge (99) between C174 and C179 located in the second 
extracellular loop (e2) was included in the hCB2 models. Out of the generated 100 models 
	   115	  
(Figure 4.3), an optimal model was chosen according to Discrete Optimized Protein Energy 
(DOPE) and molpdf scores (Figure 4.4). To remove unfavorable steric clashes and to release 
strain among amino acid residues, the model was subjected to Prime (Schrödinger 2012 suite) for 
minimization using the OPLS-2005 force field. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Cα-atom based overlay of the generated 100 models of the hCB2 receptor. Helices 
and loops are shown in magenta and blue colors, respectively. 
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Figure 4.4. Plots of DOPE (top) and molpdf (bottom) scores of the generated 100 models of the 
hCB2 receptor. 
 
4.2.2. Induced fit docking  
Since ideal allosteric modulators work only when an endogenous or synthetic ligand 
binds with the GPCR receptor, therefore; we began with flexible docking of the non-selective 
CB agonist CP 55,940 into our in-house CB2 receptor active state model (prepared by Roy et al, 
unpublished) using the Glide Induced Fit algorithm (163). CP 55,940 was sketched and geometry 
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optimized in Maestro for docking studies. The induced fit docking module of the Schrödinger 
software package was used to initially dock CP 55,940 into the CB2 model. The induced-fit 
standard-precision (SP) docking was done with the refined hCB2 model at the site with the 
centroid of residues Lys109, Thr112, Phe117, Trp194, Trp258, Lys278, and Ser285. The 
residues within 4Å of ligand poses were automatically refined using the Prime tool. 
4.2.3. Binding pockets prediction (SiteMap module of Schrödinger suite) within CB2 
receptor 
To understand the allosteric mechanisms of dihydro-gambogic acid and TBC, SiteMap 
(231) of the Schrödinger suite was used to detect the most favorable binding pockets when an 
agonist (CP 55,940) was bound with the CB2 receptor. The first 28 residues of the N-terminus 
were not included in the CB2 protein model because they are thought to be insignificant in ligand 
binding.  
4.2.4. Conformational search for DHGA and TBC  
The CB2 allosteric modulators such as TBC and DHGA were sketched in Maestro and 
prepared using the Ligprep (160) module of the Schrödinger software. The conformational 
search of all prepared allosteric modulators was performed using Macrocycle conformational 
tools of the MacroModel (232) suite of Schrödinger. The redundant conformers were removed 
using a 1 Å cutoff from the core structures.  
4.2.5 Docking of DHGA and TBC in the predicted allosteric sites 
The grids for docking of DHGA and TBC were generated through SiteMap (231) pocket 
detection output. The following residues were considered as active site residues near 3 Å of Site 
1: Ser29, Gly30, Glu32, Lys33, Val36, Leu39, Cys40, Leu43, Phe87, Ala88, Cys89, Val92, 
His95, Val96, Phe106, Ile110, Val113, Thr114, Phe117, Ser180, Glu181, Leu182, Lys278, 
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Lys279, Phe281, Ala282, Phe283, Ser285, Leu289, and Ile290 while Thr118, Ala119, Gly122, 
Leu125, Leu126, Ile156, Met157, Leu160, Ser161, Val164, Leu196, Phe197, and Leu201 were 
considered as active site residues near 3 Å of Site 4. Rigid ligand docking with standard 
precision using Glide software was performed.	  	  
4.2.6. Molecular dynamics (MD) simulation studies on the CB2–CP 55,940 complex, and of 
complexes with dihydrogambogic acid (DHGA) and trans-β-caryophyllene (TBC) with 
CB2–CP 55,940 already bound with CB2 receptor 
The best complexes of DHGA and TBC with the CP 55,940-CB2 receptor complex were 
further used to prepare MD input files. The POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine) membrane was placed in the complexes using the CHARMM-GUI webserver 
(233). The stream files for DHGA and TBC were generated using the Paramchem (234) server 
for preparing CHARMM topological and parameter files for further preparation of the lipid-
protein system. The hydrated POPC bilayer systems of CB2-CP 55,940-AMs complexes were 
prepared and further equilibrations and a production run were carried out for 200 ns using 
NAMD (235) software. Trajectories analysis was done by VMD software (236). 
4.2.7. SBVS using the allosteric modulator-optimized complexes  
We downloaded 181,317 compounds from the subset of natural products of the Zinc 
database and further prepared and filtered the database using the LigPrep (160) module of 
Schrödinger with the following criteria: molecular weight ≤ 700, log P ≤ 5, hydrogen bond donor 
≤ 5, hydrogen bond acceptor ≤ 10, number of rotatable bonds ≤ 10, polar surface area >80 Å and 
<140 Å and log HERG > –5 and removed reactive functional group. The allosteric modulator-
optimized CB2 receptor models from the MD simulations were used for SBVS of the filtered 
natural product database. We considered water molecules for virtual screening study that has 
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interactions directly or indirectly with amino acids of the CB2 receptor and AMs. The grids for 
Glide XP-docking were prepared using CB2-CP 55,940-TBC and CB2-CP 55,940-DHGA 
optimized complexes where TBC and DHGA were taken as the centroid of the grid, respectively. 
No additional constraint was used when preparing the grids. The top seven hits on the basis of 
best docking score and visual inspection of interactions between allosteric ligands and CB2 
receptors were selected for further evaluation by in vitro biological activity. 
4.2.8. In vitro biological evaluation for CB2 allosteric modulators 
To evaluate the allosteric effects of the allosteric modulators on orthosteric ligand 
binding, we measured changes in specific binding of the non-selective CB2 agonist [3H] CP 
55,940 and inverse agonist [3H]-SR 144528 to the CB2 wild-type receptor in the presence of 
allosteric modulators at various concentrations. 
For the binding experiments, tritium labeled [3H] CP 55,940 (CB1/CB2 agonist) or [3H] 
SR 144528 and non-tritium labeled CP 55,940 was purchased from Perkin-Elmer Life Sciences 
Inc. (Boston, MA, U.S.A.) and Tocris Bioscience (Ellisville, MO, U.S.A.), respectively. 
Human embryonic kidney 293 (ATCC #CRL- 1573) HEK293 cells was purchased from 
American type cell culture collection (ATCC) and was stably transfected with full-length human 
recombinant cDNA for cannabinoid receptor 2 subtype purchased from OreGen. These cells 
were maintained in a Dulbecco’s Modified Eagles’ medium/F-12 (50/50) nutrient mixture 
supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 1-2% G418 sulfate 
(geneticin). The cannabinoid cell lines were kept in 5% CO2 at 37 °C. Membranes would be 
prepared by scraping the cells in a 50 mM Tris-HCl buffer, homogenized via sonication and 
centrifuged as described in the protocol. These membranes were stored at −80 °C until used for 
binding assays. Protein concentration was determined via Bio-Rad Protein assay. 
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The compounds were  tested in the primary bioassay screening at different concentrations 
for cooperativity competitive binding to the cannabinoid receptor. In general, the allosteric 
compound was added into a 96-well plate followed by 0.6 nM [3H] CP 55,940 and 10 µg of 
cannabinoid membrane re-suspended in 50 mM Tris (pH 7.4), 154 mM NaCl, and 20 mM Di-
Na-EDTA supplemented with 0.02% BSA. The cannabinoid binding assay was incubated at 37 
°C for 90 minutes. The reactions was terminated by rapid filtration using GF/C filters and would 
be washed with the buffer. The dried filters covered with scintillant and measured for the amount 
of radio-ligand retained using a Perkin Elmer Topcount (Perkin Elmer Life Sciences Inc., 
Boston, MA, USA). The non-specific binding determined in the presence of non-tritiated 1 nM 
CP 55,940. The specific binding values would be obtained by the subtraction of non-specific 
values from the total binding.  
The GTPγS binding functional assay was used to evaluate the impact of the allosteric 
modulator on CP 55,940/SR 144528-induced [35S] GTPγS binding to CB2 at various 
concentrations. In general, the unlabeled allosteric compounds were dissolved in 10 different 
concentrations using the binding buffer (50 mM Tris·HCl, 100 mM NaCl, 10 mM MgCl2, 1 mM 
EDTA, pH 7.4) preincubated with a fixed tracer CP 55,940/SR 144528. The [35S] GTPγS assay 
was performed in 96-well sample plates (Wallac) designed for the 1450 MicroBeta Counter 
(PerkinElmer). All the required components such as 50 µL allosteric solution (allosteric 
modulators), CP 55,940 (Non-specific CB agonists), 50 µL [35S] GTPγS and 50 µL membrane 
plus 20 µM guanosine 5’-diphosphate (GDP) be added to 96-well plates and incubated for 60 
min at 37 °C. The reactions terminated by rapid filtration using GF/C filters and washed with the 
buffer. The dried filters covered with scintillant and measured for the amount of radio-ligand 
retained using a Perkin Elmer Topcount (Perkin Elmer Life Sciences Inc., Boston, MA, USA). 
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The Kd and Bmax values calculated by nonlinear regression using the GraphPad Prism software 
(GraphPad Software Inc., San Diego, CA). To evaluate the interaction between the radioligands 
and the allosteric modulator, the following allosteric ternary complex model  applied: 
Y = [A]/{[A] + (KA (1 + [B]/KB)/(1 + α [B]/KB))} 
where Y denotes the fractional specific binding and  
➢ [A] and [B] denote the concentration of orthosteric and allosteric modulator, respectively 
Ø KA and KB are the equilibrium dissociation constant for orthosteric ligand and allosteric 
modulator, respectively 
Ø α is the antilogarithm of the cooperativity factor. When α=1.0, the modulator does not 
alter orthosteric ligand binding. If α is less than 1.0, the modulator reduces ligand binding 
(negative allosteric modulation). If α is greater than 1.0, the modulator increases ligand 
binding (positive allosteric modulation) 
For competition binding assays, the IC50 values were determined by nonlinear regression. Ki 
values calculated using the Cheng-Prusoff equation based on Kd values obtained from saturation 
binding analyses (128, 136, 220, 222, 237). 
4.3. Results and Discussion 
4.3.1. Docking of CP 55,940 on CB2 receptor 
The known non-selective CB agonist CP 55,940 was docked into the known orthosteric 
site of the CB2 receptor using the Induced Fit Docking (IFD) protocol of the Schrödinger 
software. The induced fit docking gave a total of 13 poses which were further used for binding-
free energy calculations using the Prime MM-GBSA module (Table 4.1) (238). The pose (Figure 
4.5) that showed the highest binding in terms of the binding-free energy values was used for 
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further calculations. The docking results were in good agreement with previous mutagenesis and 
modeling studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 Figure 4.5. 2D representation of interactions of CP 55,940 with the CB2 receptor. 
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Table 4.1. Docking scores and binding free energies for all of the docked poses of CP 55,940. 
 
 
Pose number 
Docking 
score 
Emodel value 
Binding energy 
(kcal/mol) 
1 −10.814 −89.252 −131.54 
2 −10.432 −77.002 −118.56 
3 −10.831 −90.182 −125.79 
4 −10.098 −84.849 −127.41 
5 −10.045 −77.207 −120.43 
6 −9.242 −74.521 −135.61 
7 −9.203 −75.927 −119.57 
8 −9.167 −75.676 −103.80 
9 −10.304 −74.382 −102.37 
10 −9.489 −71.529 −116.85 
11 −10.388 −70.913 −103.69 
12 −10.108 −79.800 −113.50 
13 −10.300 −82.124 −104.45 
 
4.3.2. Binding pockets prediction 
Five potential allosteric binding pockets (represented as spheres with unique color for 
each pocket) were found within the CB2 receptor with bound agonist CP 55,940 using SiteMap  
(231) pocket search analysis (Fig 4.6). SiteMap identifies sites analogous to Goodford’s GRID 
algorithm with its particular definition of hydrophobicity. SiteMap performs calculation in three 
steps: 1) A grid setup and points are grouped into sets, 2) The sites are mapped into another grid 
for visualizing maps, 3) Properties evaluation and generation of sites.   
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Figure 4.6. Five potential allosteric binding pockets (represented as spheres with unique colors 
for each pocket) within the CB2 receptor with bound agonist CP 55,940 (shown with cyan 
carbon as stick representation), as determined using SiteMap. 
 
The appearance of the map types (Fig 4.7) is as follows: 
• Hydrophobic map—yellow mesh 
• Hydrophilic map—green mesh 
• Hydrogen-bond donor map—blue mesh 
• Hydrogen-bond acceptor map—red mesh 
• Metal-binding map—pink mesh 
	   Pocket	  1	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Figure 4.7.  Binding Map of pocket 1 (site 1) in the presence of bound agonist CP 55,940 
(shown with cyan carbon in CPK representation) within the CB2 receptor. 
 
The selection of the best pockets was based on SiteScore, Dscore (Druggability score), 
volume, and size of the pockets. If SiteScore and Dscore were found to be higher than 1, then the 
predicted site/pocket is more promising. By considering these parameters, only the two best 
scoring pockets near the extracellular regions of the CB2 receptor were chosen for allosteric 
binding sites. All parameters (SiteScore, Dscore, volume and size of the pockets) of the 
identified sites are shown in Table 4.2. 
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Table 4.2. Predicted binding site scores using SiteMap. 
 
4.3.3. Conformational search {dihydrogambogic acid (DHGA) and trans-β-caryophyllene 
(TBC)} 
DHGA and TBC are macromolecules; therefore, we performed a conformational search 
to identify low energy conformers for these molecules. Since DHGA was in a racemic form, we 
considered separately the R and S isomers of this molecule for our conformational search. The 
following numbers of conformers were obtained at the final stage of the conformational search: 
1)  Dihydro-GA (S-isomer)         278 
2)  Dihydro-GA (R-isomer)         252 
3)  Trans-β-Caryophyllene           8 
4.3.4. Docking analysis of TBC and DHGA in presence of CP 55,940 within the CB2 
receptor 
The low energy conformers of TBC and DHGA were docked into the CB2 receptor 
where CP 55,940 is already bound within the orthosteric site of the CB2 receptor. Docking	  results	   revealed	   that	   DHGA exhibited hydrogen bonding with Ser180 and Lys278 and 
exhibited π-π stacking with His95. The alkyl chain was oriented towards the hydrophobic 
Predicted Sites SiteScore Size Dscore Volume 
Site 1 1.159 179 1.230 475.741 
Site 2 1.079 104 1.114 283.318 
Site 3 0.973 60 1.071 157.780 
Site 4 0.810 46 0.776 179.389 
Site 5 0.858 32 0.866 72.030 
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residues Phe87, Ala88, Val92, and Phe117 of the CB2 receptor. TBC exhibited strong 
hydrophobic interactions with residues Phe87, Val92, Ile110, Phe117, and Phe281 (Fig. 4.8). 
 4.3.5. Molecular dynamics (MD) simulation studies 
In order to examine the stability of the docked poses on the CB2 receptor at the binding 
site(s), MD simulations have been performed in POPC-associated receptor models. We followed 
the same protocol for MD simulations described in chapter 3 under the MD section. We 
performed 200 ns simulations for three cases; 1) MD simulation of the CB2 receptor with the 
orthosteric ligand (CP 55,940) only; 2) MD simulation of the CB2 receptor with TBC when the 
orthosteric ligand (CP 55,940) is already bound within the CB2 receptor; 3) MD simulation of 
the CB2 receptor with DHGA when the orthosteric ligand (CP 55,940) is already bound within 
the CB2 receptor. The root mean square deviation (RMSD) graph vs time indicates that after a 
20 ns simulation in each of the three simulations, protein and ligands attained the significant 
stable pose throughout the 200 ns. The major RMSD fluctuation arises at the starting of 
simulations because the ligands shifted a little intracellularlly to attain a stable pose. Figure 4.12 
shows the overlay of the first, 50,00 frame and last frames of the simulation to understand the 
variations in ligands as well as proteins position during the time.  The RMSD plots of protein 
(CB2 receptor) and ligands vs time are shown in Figure 4.9 (A, B, and C). We performed a 
dihedral principle component analysis (dPCA) using grcarma software (239) for clustering the 
DCD files obtained from the molecular dynamics. The dPCA clustering provides the average 
clusters, superposition clusters, and representative clusters from the total DCD trajectories. The 
output format of all clusters is pdb. The average cluster pdb files consist of the average structure 
of the frames contained in the nth cluster, while the superposition cluster contains superpositions 
of the frames of the nth cluster. 
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Figure 4.8. The 3D representation of putative binding sites of (A) DHGA (yellow carbon) and 
(B) TBC (green carbon) in the presence of CP 55,940 (maroon carbon) with the CB2 receptor-
using pocket 1. 
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Figure 4.9. MD simulation of the CB2 receptor with (A) orthosteric ligand (CP 55,940) only and  
with (B) TBC and (C) DHGA in the presence of CP 55,940 within the CB2 receptor. 
 
Moreover, the representative cluster pdb files contain the natural structure with the smallest 
deviation from the average. The interaction between the CB2 receptor and allosteric ligands 
(TBC and DHGA) from MD are shown in Figures 4.10 and 4.11 using representative structures 
from dPCA analysis. The representative structure of TBC showed strong hydrophobic 
interactions with Val36, Phe87, Phe91, Val92, Phe106, Leu182, Val96, Phe281, and Ala282. 
When we overlap the initial structure with this conformation, we observed that this structure 
slightly moved towards the intracellular region and showed strong hydrophobic interactions 
compared to the initial simulation structure. In the case of the representative structure of DHGA, 
it shows H-bonding with Lys279 and had interactions with a few water molecules. DHGA also 
showed strong hydrophobic interactions with Val36, Ala37, Cys40, Val92, Phe94, Phe281, 
Ala282, Phe283, Met286, and Leu289. We further used these representative structures of CB2–
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CP 55,940, CB2–CP 55,940-TBC, and CB2–CP 55,940-DHGA for calculating their binding free 
energies using Prime MM-GBSA module of the Schrödinger software (238). In general, the 
negative allosteric modulators decreased the binding affinity of the endogenous or synthetic 
ligands while positive allosteric modulators increased the binding affinity of the endogenous or 
synthetic ligands. The efficacy of the compounds also depends on the nature of the AMs. In this 
study, the binding free energy of CP 55,940 was reduced when TBC or DHGA is bound within 
the allosteric site of the CB2 receptor. The reduced free energy of CP 55,940 in the presence of 
TBC or DHGA may confirm the nature of compounds as negative allosteric modulators (Table 
4.3).  
 
Table 4.3. Binding free-energy computation (representative conformations from each of the 
three MD simulations). 
 
 
 
Complex with CB2 
receptor 
 
Cluster based on dihedral angle 
principal component (dPCA) 
 
Binding free-energy 
of CP 55,940 with or without 
adjacent AMs within CB2 
receptor 
(kcal/mol) 
CB2–CP 55,940 I −149.13 
 II −143.92 
CB2–CP 55,940 - TBC I −125.78 
 II −135.00 
CB2–CP 55,940–DHGA I −122.76 
 II −129.45 
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Figure 4.10.  (A) 3D diagram of representative structure of TBC (plum carbon) with CB2 
receptor in the presence of CP 55,940 and (B) 2D interaction diagram of TBC with CB2 receptor 
from MD simulation results. 
 
 
 
 
A 
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Figure 4.11. (A) 3D diagram of representative structure of DHGA (yellow carbon) with CB2 
receptor in the presence of CP 55,940 and (B) 2D interaction diagram of DHGA with CB2 
receptor from MD simulation results. 
 
 
 
 
A 
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Figure 4.12. Overlay representation of first, middle, and last frames of each of the three 
molecular dynamics simulations. MD simulation of the CB2 receptor with (A) orthosteric ligand 
(CP 55,940) only; (B) DHGA; and (C) TBC in presence of CP 55,940 within CB2 receptor. The 
ligands and protein color represents: first frame (carbon in yellow), 5000th frame (carbon in 
gray) and last frame (carbon in blue). 
A 
B 
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4.3.6. SBVS using the allosteric modulator-optimized complexes 
After validation of the models, we performed SBVS using the best allosteric optimized 
CB2-CP 55,940 complexes. The top seven hits (Figure 4.13) on the basis of docking score and 
visual inspection of interactions between allosteric ligands and CB2 receptors were selected for 
further evaluation by in vitro biological activity.  
 
 
Figure 4.13. Predicted CB2 allosteric modulators identified through structure-based virtual 
screening. 
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The preliminary % displacement results of the PP101-107 compounds against the CB1 
and CB2 receptors in radioactive competition assays showed no significant CB affinity at 10 µM 
concentrations, except PP103, which further support that these compounds may act as allosteric 
modulators. Since two compounds (PP103 and PP105) showed >40% CB2 displacement, it may 
be presumed that they could be identified as biotopic (ago-allosteric or inverse ago-allosteric). 
We already submitted these compounds for testing for allosteric activity for the CB2 receptor. 
Table 4.4. The preliminary % displacement of the PP101-107 compounds against the CB1 and 
CB2 receptors in radioactive competition assays. 
Compound Code CB1 % Displacement CB2 % Displacement 
PP101 36.2 17.1 
PP102 39.1 16.0 
PP103 80.6 56.7 
PP104 4.1 8.5 
PP105 - 43.3 
PP106 6.9 5.5 
PP107 37.7 27.2 
 
4.4. Conclusion 
We have identified allosteric binding site(s) for known micromolar active allosteric 
modulators (AMs), TBC and DHGA within the CB2 receptor. We calculated the binding free 
energy of CP 55,940, which varied, with the nature of AMs bound within the allosteric site of the 
CB2 receptor. Binding of either TBC or DHGA (known as negative AMs) reduced the binding 
free-energy of CP 55,940, and thus validated the identified allosteric sites for these AMs. The 
identified allosteric sites were further used for the identification of new selective and potent CB2 
	   137	  
allosteric modulators using the SBVS approach. We have identified seven hits from SBVS, 
which were further submitted for biological evaluation to see allosteric effects against the CB2 
receptor using radioactive binding and GTPγS binding functional assays.  
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CHAPTER 5 
 
 
 
 
 
Summary and Conclusions 
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5.1. Summary 
Cannabis, also known as marijuana, is one of the oldest and most famous medicinal 
plants. Having been used for recreational and medicinal purposes for several centuries (33), it 
has been used to treat various diseases, such as arthritis, glaucoma, inflammation, cancer, etc. 
(141). To date, at least 111 cannabinoids have been isolated and identified from the Cannabis 
plant (41); Δ9-THC is the most psychoactive constituent (36). Cannabinoids exert their action by 
acting on cannabinoid receptors. Cannabinoid receptors belong to the G-protein coupled 
receptors (GPCR) Class-A rhodopsin-like family (109). GPCRs are targets of approximately 40-
50% of FDA approved drugs (1, 191). Successful drug candidates often exhibit functional 
selectivity for these targets. There are two subtypes of cannabinoid (CB) receptors, CB1 and 
CB2, which have been implicated in a wide variety of important roles in human health and 
disease. A proper and detailed understanding of the CB receptor, potential binding pockets, and 
CB-ligand binding modes may assist the discovery of new potential therapeutics targeting CB 
receptors; however, neither CB receptor subtype has been successfully crystallized nor has it had 
its three-dimensional (3D) structure experimentally characterized. Researchers explore the fields 
of endocannabinoids, cannabinoid receptors, and ligands using experimental and computational 
tools; however, wide variations in CB modulatory activity (both affinity and specificity) have 
been observed but have gone unexplained for wide classes of Cannabis-derived natural 
compounds. In Chapter 2 of this dissertation, we reported the first systematic computational 
docking and free-energy calculations conducted on a set of 25 Cannabis-derived compounds in 
order to understand their interaction pattern and observed structure-activity relationship (SAR) 
against the CB1 and CB2 protein models. This study revealed the importance of key residues of 
CB1 and CB2 receptors that are engaged in H-bonding, aromatic stacking, and hydrophobic 
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interactions with the ligand. Docking studies explained the key interactions residues (Val161, 
Thr114 and Trp194) of CB2 receptor with C-8 hydroxyl group and C-3 alkyl chain length of 
cannabinol class of compounds, which led to CB2 selectivity over CB1 receptor. Furthermore, 
important structural features of α and β-hydroxyl substituted Δ9-THC and Δ8-THC related 
compounds at C-8 and C-10 positions have been justified in terms of intra-hydrogen bonding for 
stabilization of ligand with receptor binding. The docking study also revealed the importance of 
a hydroxyl group in compounds 24 and 25. These hydroxyl groups were found to be H-bond 
donors/acceptors corresponding to particular amino acids, which might be responsible for 
cannabimimetic response. 
CB1 receptor inverse agonists have been used to treat obesity, obesity-related cardio-
metabolic disorders, and substance abuse, with some clinical success (192-194). The drug 
rimonabant has been used to demonstrate the druggability of the CB1 receptor antagonists (192). 
Patients in phase III clinical trials with rimonabant showed successful weight loss and 
improvements in metabolic disorders; however, severe psychiatric side effects, such as 
depression, anxiety, nausea, and dizziness, were also observed. Rimonabant was never approved 
by the US FDA for sale in the US and was removed from the market in Europe due to its adverse 
CNS effects (59).  
Natural products continue to be a major source of new and structurally diverse leads. 
Natural product drug discovery outlines many important drugs that revolutionized the treatment 
of several diseases over several decades (164). In view of this, the present work utilized the 
ZINC database subset of natural products to discover new natural product chemotypes as CB 
modulators using structure based virtual screening approach. We identified three virtual 
screening hits PCB-2, PCB-12 and PCB-16 in our study. These structures are novel and showed 
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promising nanomolar to micromolar range functional activity towards CB1 and CB2 receptors. 
In the next step, we purchased the analogs of these compounds and structural exploration of 
these hits resulted in nanomolar range compounds and which are highly selective for CB1 (PCB-
28, PCB-210, PCB-211 and PCB-163) and CB2 (PCB-22, PCB-23, and PCB-164) receptors.  
In addition, selective activation of CB2 is a validated therapeutic approach for such 
important human ailments as pain, inflammation, multiple sclerosis, cancer, ischemic/reperfusion 
injury, and osteoporosis (97); however, prolonged activation of the CB2 receptor may cause 
immunosuppression and bone loss (89, 134, 135). Allosteric modulators (AMs), which can be 
either positive allosteric modulators (PAMs) or negative allosteric modulators (NAMs). The CB2 
receptor’s AMs include both PAMs and NAMs. AMs can have therapeutic advantages over 
orthosteric ligands; they may exhibit reduced off-target side effects or enhanced target 
specificity. Only a few CB2 AMs with micromolar activity have been identified, and the CB2 
receptor’s allosteric site(s) is not well characterized; therefore, in order search for new potent 
AMs efficiently, we aim to identify and characterize allosteric site(s) of known negative CB2 
AMs (136)(dihydro-gambogic acid (DHGA) and trans-β-caryophyllene (TBC)) and their 
potential modes of interaction with the CB2 receptor. To achieve this aim, first of all we docked 
CP 55,940, a non-selective CB agonist on multitemplate-based active state model of CB2 
receptor. The most optimized pose that matched with the experimental mutagenesis data was 
selected for further calculations. In the next step, allosteric binding site(s) for TBC and DHGA 
were mapped within the CB2 receptor with the presence of CP 55,940 at orthosteric site using 
SiteMap. After identification of potential allosteric binding site(s) within CB2 receptor, both 
TBC and DHGA were docked on CB2 receptor when CP 55,940 was already bound within CB2 
receptor. Further, 200 ns molecular dynamics simulations were carried out using the best 
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docking poses of TBC and DHGA in the presence of CP 55,940 bound ligand within the CB2 
receptor to study the overall stability of the receptor-ligand complexes and important changes in 
the binding interactions. The dynamics results were clustered using dihedral principal component 
analysis approach (dPCA). The representative structures from dPCA analysis were chosen to 
calculate the binding free energy of CP 55,940 bound within the allosteric site of the CB2 
receptor with AMs. Binding of either TBC or DHGA (known as negative AMs) reduced the 
binding free energy of CP 55,940, and thus validated the identified allosteric sites for these AMs. 
The identified allosteric sites were further used for the identification of new selective and potent 
CB2 allosteric modulators using the SBVS approach. We have identified seven virtual hits from 
SBVS, which were further submitted for biological evaluation to see allosteric effects against the 
CB2 receptor using radioactive binding and GTPγS binding functional assays.  
Conclusions 
The studies presented in this dissertation have contributed significantly to the 
advancement of cannabinoids research. The findings of this dissertation can be concluded in the 
following points: 
1. Our systematic computational studies on Cannabis-derived compounds revealed the 
importance of particular functional groups/moieties, such as C-8 hydroxyl group and C-3 alkyl 
chain length of cannabinol class of compounds, which exhibited strong interactions with the CB2 
receptor and, hence, lead to CB2 activity and selectivity. Furthermore, the role of intramolecular-
hydrogen bonding for stabilization of ligand with receptor binding has been explored considering 
α- and β-hydroxyl substituted Δ9-THC and Δ8-THC related compounds at the C-8 and C-10 
positions. On the basis of our computational analysis on these Cannabis-derived compounds, 
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new analogs can be proposed and further synthesized and tested for CB2 activities, which might 
serve as hits for further optimization and future drug development. 
2. Our protein structure-based virtual screening has identified potent and novel natural product 
derived chemotypes as CB1 inverse agonists (such as PCB-211 and PCB-16 in subnanomolar to 
nanomolar activities, respectively), which could be useful as starting points for further studies to 
identify optimized drug leads for eventual development as antiobesity drugs. 
3. In chapter 4, we have identified and validated CB2 allosteric site(s) for negative allosteric 
modulators (TBC and DHGA) by applying computational approaches. We also identified seven 
CB2 allosteric modulators using a SBVS approach. These compounds are undergoing biological 
evaluation and might serve as selective and higher affinity CB2 allosteric modulators. 
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SUMMARY OF SKILLS/ QUALIFICATIONS 
 
Experience with instruments, software’s and techniques on Synthetic organic chemistry and 
analytical Chemistry as following: 
• Research skills: Performed Computational-modeling studies using Schrödinger, 
Gaussian 09, PatchDock, Fiber Dock, Sybyl, MOE, NAMD, Zap suite in OpenEye 
software. Also have an experience to handle various graphics software such as Pymol, 
Gaussian View 03, VMD etc. 
• Synthesis of various types of the compounds using the unique types of the reaction 
having the plethora of application in organic and medicinal chemistry like Grignard 
Reaction, reduction, acid amine coupling, Schiff bases synthesis etc., having the 
knowledge of various equipment handling like Spectrophotometer, Infra red 
spectrophotometer, Chromatotron apparatus for Purification, Various types of the 
Chromatography, knowledge of general lab procedures, Spectral analysis of the data 
problem solving and drawing of conclusions, strong theoretical background. Attended the 
demonstrative session for the combi flash, genevac evaporator and for LC-MS.    
• Computer skills: Basic, MS Office, Systat and Valstat for molecular modeling 
purpose, Discovery Gate, Belstein. 
• Project management skills: Initiation, evaluation, development and execution of various 
science and pharmaceutical related projects during teaching of 20-25 people. 
• Communication and Presentation Skills: experienced giving scientific and educational 
talks during the bachelor’s and master’s program. 
• Energetic, detail-oriented, able to multi-task and work well as part of a team. 
 
MEMBERSHIPS (PROFESSIONAL AND HONORARY SOCIETIES)  
 
• Serving as a Director of International Student Affairs in the Graduate Student Council 
(GSC), at the University of Mississippi (2014-2015). 
• Registered Pharmacist, Under M. P. State Pharmacy Council, India; Registration No. 
13106.  
• Graduate Student Senator of Department of Medicinal Chemistry (Aug2012-Aug2013). 
• Selected Who’s Who class for The University of Mississippi 2013-2014. 
• Served as a Co-Director of Academic and Professional Development 2013-2014 in 
Graduate Student Council (GSC) at University of Mississippi. 
• Certificate of Achievement in recognition of Nobel Sam Research Award at the Honors 
convocation, at The University of Mississippi (April 10, 2014). 
• GRE: 1290 (V-530, Q-760, A-2.5) 
• Professional Membership 
• AAAS  
• Rho Chi Honor Society  
• AAPS 
• ACS  
• Phi Kappa Phi Honor Society 
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• National Association of Graduate and Professional Students  
 
 
POSITIONS OF RESPONSIBILITY 
 
• Management Representative for Swami Vivekanand College of Pharmacy for ISO 
2001:2008 certifications. 
• Organizing committee member National seminar on Current Trends in Challenges in 
Pharmaceutical Sciences at SVCP, Indore on 7th March’ 2009. 
• Member of the committees formed for the International symposium Current Trends in 
Drug Discovery Research (CTDDR-07), held at CDRI, Lucknow, India. 
• In charge of Sophisticated Instrumental Laboratory, Swami Vivekanand College of 
Pharmacy, Indore. 
 
 
SERVICE AND EXTRA-CURRICULAR ACTIVITIES 
 
• Graduate Student Senator of Department of Medicinal chemistry (Aug2012-Aug2013). 
• Served as a member of Instructional Resources and Computing Committee (IRC) at School 
of Pharmacy, University of Mississippi 2012-2013. 
• Served as an active member of the Chancellor’s Standing Committees under the Instructional 
Resources and Computing Committee (IRC), University of Mississippi 2013-2014. 
• Served as a Co-Director of Academic and Professional Development 2013-2014 in 
graduate student council (GSC) at University of Mississippi 
• Served as a judge in the District Science Fair at Della Davidson Elementary School 
in Oxford, MS (2012, 2013 and 2015) and the Mississippi Regional VII Science Fair in the 
Tad Smith Coliseum, Oxford, MS (2013 and 2014). 
• Team Leadership: Captain of the following two Inter-Department Teams Events: Quiz, 
Cricket for the session 2004-06. 
• Participated and won many prizes in Quizzes, Elocutions, and Skits in School and College. 
• Hobbies: Reading, playing chess. 
• Enthusiastic about social services, involved in various activities to spread awareness in 
rural areas with NGO’s in city of Indore. 
 
